

(51) International Patent Classification:

C07K 14/52 (2006.01) C07K 14/55 (2006.01)

A61K 38/19 (2006.01) C07K 14/715 (2006.01)

A61K 38/20 (2006.01) C12N 15/62 (2006.01)

C07K 7/08 (2006.01)

(21) International Application Number:

PCT/US2020/046244

(22) International Filing Date:

13 August 2020 (13.08.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/886,148 13 August 2019 (13.08.2019) US

(71) Applicant: ELPIS BIOPHARMACEUTICALS

[US/US]; 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US).

(72) Inventors; and

(71) Applicants: HASSAN, Samuel Clement [GB/US]; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US). JIANG, Ning [US/US]; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US).

(72) Inventors: CHEN, Yan; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US). ZHAO, Kehao; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US). SWANSON, Christina; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US). NGUYEN, Jenna; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US). KALLEN, Nathan; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US).

(74) Agent: O'BRIEN, Daniel et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ENGINEERED INTERLEUKIN-2 RECEPTOR BETA AGONISTS

APTSSSTKKITQLQLEHLLLDLQMIILNGINNYKNPKLTRMLTFKIFYMPKKATELKHLCLEE
ELKPLEEVLNIAOSKNFHLRPRDLISNINVIVLEIKGSETTFMCEYADETATIVEFLNRWI
TECQSIISTLT (SEQ ID NO: 22)

FIG. 1A

(57) Abstract: Provided herein are engineered IL2 polypeptides and fusion proteins thereof. Also provided are methods of modulating an immune response by administering an engineered IL2 polypeptide or a fusion protein thereof. The engineered IL2 polypeptides and fusion proteins thereof demonstrate increased binding to IL2R β , decreased binding to IL2R α , or both.

ENGINEERED INTERLEUKIN-2 RECEPTOR BETA AGONISTS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to U.S. Provisional
5 Application No. 62/886,148, filed August 13, 2019, which is hereby incorporated by
reference in its entirety.

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided in text
10 format in lieu of a paper copy, and is hereby incorporated by reference into the
specification. The name of the text file containing the Sequence Listing is
300096_401WO_SEQUENCE_LISTING.txt. The text file is 230 KB, was created on
August 13, 2020, and is being submitted electronically via EFS-Web.

BACKGROUND

15 Interleukin-2 (IL2) is a cytokine that modulates lymphocyte proliferation
and activation. It has a length of 133 amino acids and the structure includes four
antiparallel, amphipathic C-helices. IL2 mediates its action by binding to IL2 receptors
(IL2R), which includes up to three individual subunits. Association of all three
subunits, the interleukin-2 receptor alpha chain (IL2R α , or CD25), interleukin-2
20 receptor beta chain (IL2R β , or CD122), and interleukin-2 receptor gamma chain
(IL2R γ , or CD132), results in a trimeric IL2R $\alpha\beta\gamma$, which is a high-affinity receptor for
IL2. Association of the IL2R β and IL2R γ subunits results in the dimeric receptor
IL2R $\beta\gamma$, and is termed an intermediate affinity IL2R. The IL2R α subunit forms a
monomeric low affinity IL2 receptor. Expression of IL2R α is involved in the expansion
25 of immunosuppressive regulatory T cells (Tregs); whereas dimeric IL2R $\beta\gamma$ can result in
cytolytic CD8⁺ T cell and NK cell proliferation and killing in the absence of IL2R α .

BRIEF SUMMARY

The present disclosure provides engineered IL2 polypeptides having improved binding to IL2R β as compared to wild-type IL2 and/or reduced binding to IL2R α as compared to wild-type IL2.

5 In one aspect, the present disclosure provides an engineered interleukin-2 (IL2) polypeptide comprising an engineered IL2 receptor β (IL2R β) binding region 2 comprising: X₁-X₂-X₃-D-X₄-X₅-X₆-N-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃ (SEQ ID NO: 1),

wherein X₁, X₃, X₆, X₈, X₁₂, and X₁₃ each comprise any residue,

wherein X₂, X₄, and X₁₀ are uncharged residues,

10 wherein X₅, X₇, X₉, and X₁₁ each comprise uncharged, nonpolar residues, and

wherein the engineered IL2 polypeptide binds to IL2R β at a K_D at least 10-fold greater than a wild-type IL2.

In certain aspects, X₁ is an uncharged polar residue, an uncharged
 15 nonpolar residue, a basic residue, or an acidic residue; X₁ is selected from C, T, G, W, I, S, E, and K; or X₁ is selected from G, K, E, C, and T. In certain aspects, X₂ is an uncharged polar residue or an uncharged nonpolar residue; X₂ is selected from Y, P, V, W, L, A, and G; or X₂ is selected from V, P, W, and A. In certain aspects, X₃ is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic
 20 residue; X₃ is selected from S, T, Q, G, M, E, R, and K; or X₃ is selected from T, G, S, R, and E. In certain aspects, X₄ is not L; X₄ is an uncharged nonpolar residue or an uncharged polar residue; or X₄ is selected from A, V, S, and T. In certain aspects, X₅ is selected from I, L, T, and V; or X₅ is selected from I and V. In certain aspects, X₆ is an uncharged polar residue, a basic residue, or an acidic residue; X₆ is selected from S, T,
 25 E, D, and R; or X₆ is selected from S, D, E, and T. In certain aspects, X₇ is selected from I, A, M, and V; or X₇ is selected from I, A, and M. In certain aspects, X₈ is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue; X₈ is selected from S, T, N, Q, I, G, E, K, and R; or X₈ is selected from I, R, N, and T. In certain aspects, X₉ is selected from V, L, and I; or X₉ is V. In certain aspects,
 30 X₁₀ is an uncharged polar residue or an uncharged nonpolar residue; X₁₀ is selected from N, T, I, and L; or X₁₀ is selected from I and L. In certain aspects, X₁₁ is a uncharged nonpolar residue; or X₁₁ is selected from V, A, and I. In certain

embodiments, X₁₂ is an uncharged polar residue, an uncharged nonpolar residue, or an acidic residue; X₁₂ is selected from Q, L, G, K, and R; or X₁₂ is selected from R, G, Q, and K. In certain aspects, X₁₃ is an uncharged nonpolar residue or a basic residue; X₁₃ is selected from A, D, and E; or X₁₃ is selected from E and A.

5 In some aspects, the present disclosure provides an engineered IL2 polypeptide comprising a substitution to at least one residue selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94. In certain aspects, the R81 substitution is selected from R81G, R81K, R81E, R81C, and R81T; the R83 substitution is selected from R83T, R83G, R83S, and R83E; the L85 substitution is
10 selected from L85S, L85A, L85V, and L85T; the I92 substitution is I92L; and the L94 substitution is selected from L94R, L94G, L94Q, and L94K. In certain aspects, the engineered IL2 polypeptide comprises substitutions to R81 and L83. In certain aspects, the engineered IL2 polypeptide comprises substitutions to R81, L83, S87, N90, and N94; substitutions to R81, L83, S87, N90, and V93; substitutions to R81, L83, P82, and
15 V93; or substitutions to R81, L83, and N90.

 In one aspect, the present disclosure provides an engineered interleukin-2 (IL2) polypeptide comprising an engineered IL2 receptor α (IL2R α) binding region 1 motif. comprising a substitution selected from: a substitution at position K35, a substitution at R38, a substitution at F42, a substitution at Y45, or combinations thereof,
20 wherein the engineered IL2 polypeptide binds to IL2R α with at least 2-fold reduced binding kinetics as compared to wild-type IL2.

 In some aspects, the present disclosure provides an engineered IL2 polypeptide including an engineered IL2 receptor β (IL2R β) binding region 2 as previously described and an engineered IL2 receptor α (IL2R α) binding region 1 as
25 previously described.

 In some aspects, the present disclosure provides an engineered IL2 polypeptide as provided herein, fused to a half-life extending molecule.

 In some aspects, the present disclosure provides a fusion polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide
30 comprises an engineered IL2 polypeptide as provided herein.

 In some aspects, the present disclosure provides an isolated polynucleotide encoding an engineered IL2 polypeptide or a fusion polypeptide thereof,

an expression vector comprising the isolated polynucleotide, or a modified cell comprising the isolated polynucleotide or expression vector.

In some aspects, the present disclosure provides a pharmaceutical composition comprising the engineered IL2 polypeptide or fusion polypeptide thereof,
5 and a pharmaceutically acceptable carrier.

In some aspects, the present disclosure provides a method of modulating an immune response in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide or fusion polypeptide thereof, or a pharmaceutical composition thereof. In certain aspects,
10 modulating the immune response comprises at least one of: enhancing effector T cell activity, enhancing NK cell activity, and suppressing regulatory T cell activity.

In some aspects, the present disclosure provides a method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide or fusion
15 polypeptide thereof, or a pharmaceutical composition thereof. In certain aspects, the disease is cancer. In certain aspects, the method further comprises administering an additional therapeutic agent, such as an antigen binding moiety, an immune cell expressing a chimeric antigen receptor, an immune cells expressing an engineered T cell receptor, a tumor infiltrating lymphocyte, an immune checkpoint inhibitor, an
20 oncolytic virus, a tumor microenvironment (TME) inhibitor, or a cancer vaccine. In certain aspects, the methods comprise administering to the subject an immune cell comprising a polynucleotide encoding the engineered IL2 polypeptide or fusion polypeptide thereof.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

25 Fig. 1A shows the regions of IL2 responsible for binding IL2R α (solid open boxes), IL2R β (dashed boxes), and IL2R γ (gray boxes), Fig. 1B shows a graphic depiction of IL2R α , IL2R β , and IL2R γ bound to IL2, and Fig. 1C shows the IL2R α binding site of IL2 highlighting four residues (K35, R38, F42 and Y45) of IL2 critical for IL2R α interaction.

Figs. 2A-2B show the identification of IL2R α reduced binding mutations by ELISA.

Fig. 3 shows characterization of IL2R α -reduced binding mutations by surface plasmon resonance sequence alignments of IL2R α reduced binding mutations.

5 Fig. 4 shows characterization of IL2R α -reduced binding mutations by surface plasmon resonance.

Fig. 5 shows the IL2R β agonist mutagenic libraries

Fig. 6 shows IL2R β agonist expression in *E.coli* and binding to IL2R β .

Fig. 7 shows a multiple sequence alignment of the IL2R β binding region
10 2 for IL2R β agonists identified through mRNA display.

Fig. 8 shows SDS analysis of IL2R β agonist clones produced in *E. coli*.

Figs. 9A-9B show sensorgrams and binding kinetics of wild-type IL2 to IL2R α (Fig. 9A) and IL2R β (Fig. 9B) in SPR.

Figs. 10A-10H show sensorgrams of *E. coli* produced wild-type IL2 and
15 engineered IL2R β agonists to IL2R α in SPR. Fig. 10A shows a sensorgram of wild-type IL2; Fig. 10B shows a sensorgram of EP001; Fig. 10C shows a sensorgram of EP004; Fig. 10D shows a sensorgram of EP005; Fig. 10E shows a sensorgram of EP002; Fig. 10F shows a sensorgram of EP03; Fig. 10G shows a sensorgram of EPIM-06; and Fig. 10H shows a sensorgram of EP007.

20 Figs. 11A-11H show sensorgrams of *E. coli* produced wild-type IL2 and engineered IL2R β agonists to IL2R β in SPR. Fig. 11A shows a sensorgram of EP003; Fig. 11B shows a sensorgram of EP005; Fig. 11C shows a sensorgram of E002; Fig. 11D shows a sensorgram of EP001; Fig. 11E shows a sensorgram of EP007; Fig. 11F shows a sensorgram of EP006; Fig. 11G shows a sensorgram of EP004; and Fig. 11H
25 shows a sensorgram of wild-type IL2.

Figs. 12A-12D show sensorgrams of IL2R β binding to mammalian produced wild-type IL2 (Fig. 12A) and engineered IL2R β agonists EP0001 (Fig. 12B), EP0003 (Fig. 12C), and EP004 (Fig. 12D) in SPR.

Figs. 13A-13D show sensorgrams of IL2R α binding to mammalian produced wild-type IL2 (Fig. 13A) and engineered IL2R β agonists EP001 (Fig. 13B), EP003 (Fig. 13C), and EP004 (Fig. 13D) in SPR.

5 Figs. 14A-14I show pSTAT5 expression as measured from blood donors 1-3, following stimulation of human PBMCs with wild-type IL2 and engineered IL2R β agonists, as measured for CD8+ T cells (Fig. 14A for blood donor 1, Fig. 14D for blood donor 2, and Fig. 14G for blood donor 3), NK cells (Fig. 14B for blood donor 1, Fig. 14E for blood donor 2, and Fig. 14H for blood donor 3), and T regs (Fig. 14C for blood donor 1, Fig. 14F for blood donor 2, and Fig. 14I for blood donor 3).

10 Figs. 15A-15B show characterization by ELISA of IL2R β agonist EP001 back-mutation clones for binding to IL2R α (Fig. 15A) and IL2R β (Fig. 15B) by ELISA.

Figs. 16A-16H show IL2R β binding sensorgrams of IL2R β agonist EP001 back-mutation clones by SPR.

15 Fig. 17 shows examples of SDS-PAGE results for purified clones of IL2R α /IL2R β clones.

Figs. 18A-18H show binding sensorgrams of engineered IL2R α /IL2R β clones to human IL2 α by SPR.

Figs. 19A-19H show binding sensorgrams of engineered IL2R α /IL2R β clones to human IL2 β by SPR.

20 Figs. 20A-20G show single concentration binding sensorgrams of engineered IL2R α /IL2R β clones to human IL2R α by SPR.

Figs. 21A-21G show single concentration binding of engineered IL2R α /IL2R β clones to human IL2R β by SPR.

25 Figs. 22A-22B show multi-concentration binding of engineered IL2R α /IL2R β clones to human IL2R α (Fig. 22A) and IL2R β (Fig. 22B) by SPR.

Figs. 23A-23E show ELISA binding to human IL2R α . Fig. 23A shows the ELISA binding of EP252 and its IL2R α binding reduced mutations to human IL2R α . Fig. 23B shows the ELISA binding of EP253 and its IL2R α binding reduced mutations to human IL2R α . Fig. 23C shows the ELISA binding of EP258 and its IL2R α binding reduced mutations to human IL2R α . Fig. 23D shows the ELISA binding of

30

EP260 and its IL2R α binding reduced mutations to human IL2R α . Fig. 23E shows dose dependent binding for selected engineered IL2R β /IL2R α clones.

Figs. 24A-24D show ELISA binding to human IL2R β . Fig. 24A shows the ELISA binding of EP252 and its IL2R α binding reduced mutations to human IL2R β . Fig. 24B shows the ELISA binding of EP253 and its IL2R α binding reduced mutations to human IL2R β . Fig. 24C shows the ELISA binding of EP258 and its IL2R α binding reduced mutations to human IL2R β . Fig. 24D shows the ELISA binding of EP260 and its IL2R α binding reduced mutations to human IL2R β .

Figs. 25A-25D show p-STAT5 activation of human CD8⁺ T cells from donor 656, by engineered IL2R α /IL2R β clones. Fig. 25A shows p-STAT5 activation of human CD8⁺ T cells for EP252 and its IL2R α binding reduced mutations. Fig. 25B shows p-STAT5 activation of human CD8⁺ T cells for EP253 and its IL2R α binding reduced mutations. Fig. 25C shows p-STAT5 activation of human CD8⁺ T cells for EP258 and its IL2R α binding reduced mutations. Fig. 25D shows p-STAT5 activation of human CD8⁺ T cells for EP260 and its IL2R α binding reduced mutations.

Figs. 26A-26D show p-STAT5 activation of human CD8⁺ T cells from donor 648, by engineered IL2R α /IL2R β clones. Fig. 26A shows p-STAT5 activation of human CD8⁺ T cells for EP252 and its IL2R α binding reduced mutations. Fig. 26B shows p-STAT5 activation of human CD8⁺ T cells for EP253 and its IL2R α binding reduced mutations. Fig. 26C shows p-STAT5 activation of human CD8⁺ T cells for EP258 and its IL2R α binding reduced mutations. Fig. 26D shows p-STAT5 activation of human CD8⁺ T cells for EP260 and its IL2R α binding reduced mutations.

Figs. 27A-27D show p-STAT5 activation of human NK cells from donor 656, by engineered IL2R α /IL2R β clones. Fig. 27A shows p-STAT5 activation of human NK cells for EP252 and its IL2R α binding reduced mutations. Fig. 27B shows p-STAT5 activation of human NK cells for EP253 and its IL2R α binding reduced mutations. Fig. 27C shows p-STAT5 activation of human NK cells for EP258 and its IL2R α binding reduced mutations. Fig. 27D shows p-STAT5 activation of human NK cells for EP260 and its IL2R α binding reduced mutations.

Figs. 28A-28D show p-STAT5 activation of human NK cells from donor 648, by engineered IL2R α /IL2R β clones. Fig. 28A shows p-STAT5 activation of human NK cells for EP252 and its IL2R α binding reduced mutations. Fig. 28B shows p-STAT5 activation of human NK cells for EP253 and its IL2R α binding reduced mutations. Fig. 28C shows p-STAT5 activation of human NK cells for EP258 and its IL2R α binding reduced mutations. Fig. 28D shows p-STAT5 activation of human NK cells for EP260 and its IL2R α binding reduced mutations.

Figs. 29A-29D show p-STAT5 activation of human T reg cells from donor 656, by engineered IL2R α /IL2R β clones. Fig. 29A shows p-STAT5 activation of human T reg cells for EP252 and its IL2R α binding reduced mutations. Fig. 29B shows p-STAT5 activation of human T reg cells for EP253 and its IL2R α binding reduced mutations. Fig. 29C shows p-STAT5 activation of human T reg cells for EP258 and its IL2R α binding reduced mutations. Fig. 29D shows p-STAT5 activation of human T reg cells for EP260 and its IL2R α binding reduced mutations.

Figs. 30A-30D show p-STAT5 activation of human T reg cells from donor 648, by engineered IL2R α /IL2R β clones. Fig. 30A shows p-STAT5 activation of human T reg cells for EP252 and its IL2R α binding reduced mutations. Fig. 30B shows p-STAT5 activation of human T reg cells for EP253 and its IL2R α binding reduced mutations. Fig. 30C shows p-STAT5 activation of human T reg cells for EP258 and its IL2R α binding reduced mutations. Fig. 30D shows p-STAT5 activation of human T reg cells for EP260 and its IL2R α binding reduced mutations.

Figs. 31A-31D show p-STAT5 activation of murine CD8⁺ T cells. Fig. 31A shows p-STAT5 activation of murine CD8⁺ T cells for EP252 and its IL2R α binding reduced mutations. Fig. 31B shows p-STAT5 activation of murine CD8⁺ T cells for EP253 and its IL2R α binding reduced mutations. Fig. 31C shows p-STAT5 activation of murine CD8⁺ T cells for EP258 and its IL2R α binding reduced mutations. Fig. 31D shows p-STAT5 activation of murine CD8⁺ T cells for EP260 and its IL2R α binding reduced mutations.

Figs. 32A-32D show p-STAT5 activation of murine NK cells. Fig. 32A shows p-STAT5 activation of murine NK cells for EP252 and its IL2R α binding

reduced mutations. Fig. 32B shows p-STAT5 activation of murine NK cells for EP253 and its IL2R α binding reduced mutations. Fig. 32C shows p-STAT5 activation of murine NK cells for EP258 and its IL2R α binding reduced mutations. Fig. 32D shows p-STAT5 activation of murine NK cells for EP260 and its IL2R α binding reduced mutations.

Figs. 33A-33D show p-STAT5 activation of murine T regulatory cells. Fig. 33A shows p-STAT5 activation of murine T regulatory cells for EP252 and its IL2R α binding reduced mutations. Fig. 33B shows p-STAT5 activation of murine T regulatory cells for EP253 and its IL2R α binding reduced mutations. Fig. 33C shows p-STAT5 activation of murine T regulatory cells for EP258 and its IL2R α binding reduced mutations. Fig. 33D shows p-STAT5 activation of murine T regulatory cells for EP260 and its IL2R α binding reduced mutations.

Fig. 34 shows a summary of p-STAT5 activation of murine CD8⁺ T cells, NK cells, and Tregs.

Figs. 35A-35C show structure diagrams of monovalent and bivalent IL2R β agonist Fc fusion proteins.

Figs. 36A-36B show SDS-PAGE analysis of the purified IL2R β agonist Fc fusion proteins.

Figs. 37A-37G show receptor binding analysis by ELISA of bivalent IL2R β agonist Fc fusion proteins.

Figs. 38A-38B show receptor binding analysis by ELISA of monovalent IL2R β agonist Fc fusion proteins.

Figs. 39A-39D show receptor binding analysis of monovalent IL2R β Fc fusion proteins by SPR.

Figs. 40A-40C show p-STAT5 activation of human PBMCs by bivalent IL2R β agonist Fc-fusion proteins.

Figs. 41A-41C show p-STAT5 activation of human PBMCs by monovalent IL2R β agonist Fc-fusion proteins.

Figs. 42A-42B show pharmacokinetics with murine i.v. (Fig. 42A) and i.p. (Fig. 42B) administration of IL2R β agonist.

Figs. 43A-43D show normalized counts of tumor infiltrating immune cells following administration of IL2R β agonist.

Figs. 44A-44B show ratios of effector cells to T regulatory cell in tumors.

5 Figs. 45A-45C show percentages of effector and memory T cells.

DETAILED DESCRIPTION

IL2 has been a promising new immunotherapy, but therapies based on wild-type human IL2 may activate T regulatory cells in addition to activating effector T cells and NK cells. Activation of T regulatory cells by IL2 may hamper the anti-cancer
10 response that may otherwise be elicited by IL2. Thus, IL2-based therapies with reduced activation of T regulatory cells and/or preferential activation of T effector cells, NK cells, or a combination thereof are needed.

Presented herein are rationally designed IL2R β agonists, which are engineered IL2 polypeptides having amino acid substitutions in IL2R β binding region 2
15 that enhance binding to IL2R β . The engineered IL2R β agonists provide the advantage of increasing stimulation of NK cells and T effector cells compared to wild-type IL2, but not T regulatory cells. Thus, the engineered IL2R β agonists are useful for modulating or activating an immune response, for example, for treatment of cancer.

The term “interleukin-2 or “IL2” as used herein, refers to an IL2 from
20 any vertebrate source, including mammals such humans or mice, unless otherwise indicated. The term encompasses precursor or unprocessed IL2, as well as any form of IL2 that results from cellular processing. The term also encompasses naturally occurring variants of IL2, such as splice variants or allelic variants. The amino acid sequence of an example mature human IL2 is shown in SEQ ID NO: 65. Precursor or
25 unprocessed human IL2 is shown in SEQ ID NO: 66, and includes a 20-residue signal peptide, which is absent in the mature IL2 polypeptide. “Wild-type” or “native” when used in reference to IL2 is intended to mean the mature IL2 molecule (*e.g.*, SEQ ID NO: 65). The term “engineered IL2” or “engineered IL2 polypeptide” as used herein encompasses an IL2 having at least one residue that differs from a native or wild-type
30 IL2, and includes full-length IL2, truncated forms of IL2, and forms where IL2 is linked

or fused with another molecule, such as another polypeptide. The various forms of engineered IL2 are characterized in having at least one amino acid substitution affecting the interaction of IL2 with IL2R β and/or IL2R α . Identification of various engineered forms of IL2 as described herein are made with respect to the sequence shown in, e.g.,

- 5 SEQ ID NO: 22. Various identifiers may be used herein to indicate the same residue substitution. For example, a substitution from arginine at position 81 to threonine can be indicated as R81T or 81T.

IL2R β binding region 1 and IL2R β binding region 2 are responsible for IL2 binding to IL2R β . “IL2R β binding region 1” as used herein refers to residues 11-23
10 of wild-type or native human IL2. The amino acid sequence of IL2R β binding region 1 is provided in SEQ ID NO: 67. “IL2R β binding region 2” as used herein refers to residues 81-95 of wild-type or native human IL2. The amino acid sequence of IL2R β binding region 2 is provided in SEQ ID NO: 68.

IL2R α binding region 1 and IL2R α binding region 2 are responsible for
15 IL2 binding to IL2R α . “IL2R α binding region 1” as used herein refers to residues 34-45 of wild-type or native human IL2. The amino acid sequence of IL2R α binding region 1 is provided in SEQ ID NO: 223.

The term “substitution” or “residue substitution” as used herein refers to replacement of a native or wild-type residue with a different residue.

20 “Any residue” as used herein refers to an amino acid residue having one of the twenty canonical amino acid side chains: alanine (Ala, A); arginine (Arg, R); asparagine (Asn, N); aspartic acid (Asp, D); cysteine (Cys, C); glutamine (Gln, Q); glutamic acid (Glu, E); glycine (Gly, G); histidine (His, H); isoleucine (Ile, I); leucine (Leu, L); lysine (Lys, K); methionine (Met, M); phenylalanine (Phe, F); proline (Pro, P);
25 serine (Ser, S); threonine (Thr, T); tryptophan (Trp, W); tyrosine (Tyr, Y); and valine (Val, V).

“Uncharged residue” as used herein refers to an amino acid residue with a side chain that does not hold a charge at physiologic pH (pH=7). The uncharged residues are: alanine (Ala, A); asparagine (Asn, N); cysteine (Cys, C); glutamine (Gln, Q); glycine (Gly, G); histidine (His, H); isoleucine (Ile, I); leucine (Leu, L); methionine (Met, M); phenylalanine (Phe, F); proline (Pro, P); serine (Ser, S); threonine (Thr, T);
30 tryptophan (Trp, W); tyrosine (Tyr, Y); and valine (Val, V).

“Uncharged polar residue” as used herein refers to an amino acid residue with a side chain that does not hold a charge at physiologic pH (pH=7) and is hydrophilic. The uncharged polar residues are: asparagine (Asn, N); cysteine (Cys, C); glutamine (Gln, Q); serine (Ser, S); threonine (Thr, T); and tyrosine (Tyr, Y).

5 “Uncharged nonpolar residue” as used herein refers an amino acid residue with a side chain that does not hold a charge at physiologic pH (pH=7) and is hydrophobic. The uncharged nonpolar residues are: alanine (Ala, A); glycine (Gly, G); histidine (His, H); isoleucine (Ile, I); leucine (Leu, L); methionine (Met, M); phenylalanine (Phe, F); proline (Pro, P); tryptophan (Trp, W); and valine (Val, V).

10 “Basic residue” as used herein refers to an amino acid residue with a side chain that holds a positive charge at physiologic pH (pH=7). The basic residues are lysine (Lys, K); and arginine (Arg, R).

“Acidic residue” as used herein refers to an amino acid residue with a side chain that holds a negative charge at physiologic pH (pH=7). The acidic residues
15 are aspartic acid (Asp, D); and glutamic acid (Glu, E).

“Fusion polypeptide” or “fusion protein” refers to a polypeptide that is encoded by at least two different DNA sequences corresponding to genes or fragments thereof, which are not naturally expressed from the same gene. An example of a fusion polypeptide is an engineered IL2-Fc fusion polypeptide, which includes an amino acid
20 sequence of an engineered IL2 polypeptide and an amino acid sequence of an Fc domain.

“Affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (*e.g.*, a receptor) and its binding partner (*e.g.*, a ligand). Unless indicated otherwise, as used herein, “binding affinity”
25 refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (*e.g.*, receptor and a ligand). The affinity of a molecule-X for its partner Y can generally be represented by the dissociation constant (K_D), which is the ratio of dissociation and association rate constants (k_{off} and k_{on} , respectively). Thus, equivalent affinities may comprise different rate constants, as long as the ratio of the rate constants
30 remains the same. Affinity can be measured by methods known by persons of skill in the art, including those described herein.

“Half-life extending molecule” as used herein refers to a molecule that when attached (*e.g.*, covalently) to a second molecule, extends the half-life of the second molecule. Examples of half-life extending molecules include an Fc domain, human serum albumin (HSA), an HSA binding molecule, polyethylene glycol (PEG),
5 and polypropylene glycol (PPG).

“Fc domain” or “Fc region” as used herein refers to a polypeptide derived from a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes polypeptides having a native sequence Fc region, or variants thereof. Although the boundaries of the Fc region of an
10 IgG heavy chain might vary slightly, the human IgG heavy chain Fc region is usually defined to extend from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Examples of Fc regions are disclosed in US Patent No. 7,317,091; US Patent No. 8,735,545; US Patent No. 7,371,826; US Patent No. 7,670,600; and US 9,803,023;
15 all of which are incorporated by reference in their entirety.

“Human serum albumin” or “HSA” refers to the serum albumin found in human blood. The commonly used form of HSA has a molecular mass of 66.5kDa and a half-life of approximately 20 days. Examples of HSA molecules are disclosed in US Patent No. 8,143,026 and US Patent No. 7,189,690, which are incorporated by
20 reference in their entirety.

“HSA binding molecule” refers to a molecule that specifically binds to human serum albumin (HSA), such as an antigen binding moiety having an HSA binding domain.

“Polyethylene glycol” or “PEG,” also referred to as polyethylene oxide or polyoxyethylene is a polyether polymer that may be used to extend half-life.
25

“Polypropylene glycol” or “PPG,” also referred to as polypropylene oxide, is a polymer of propylene glycol that may be used to extend half-life.

“Antigen binding moiety” refers to the site (*i.e.*, amino acid residues) of an antigen binding molecule (*e.g.*, antibody) that provides interaction with the antigen
30 epitope. An antigen binding moiety may include one or more antibody variable domains (also called antibody variable regions). Preferably, an antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain

variable region (VH). Examples of antigen binding moieties include immunoglobulins, Fab molecules, scFv, bispecific antibodies, diabodies, bi-specific T-cell engagers, and nanobodies. Specific examples of antigen binding moieties include nivolumab, pembrolizumab, pidilizumab, atezolizumab, ipilimumab, tremelimumab, rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, ublituximab, and bevacizumab.

“Immunoglobulin” refers to a protein having the structure of a naturally occurring antibody. As an example, immunoglobulins of the IgG class are heterotetrameric glycoproteins with two light chains and two heavy chains that are disulfide-bonded. From N- to C-terminus, the heavy chains each have a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called a heavy chain constant region. Similarly, from N- to C-terminus, light chain each have a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain, also called a light chain constant region. The heavy chain of an immunoglobulin may be assigned to one of five classes, called α (IgA), δ (IgD), ϵ (IgE), γ (IgG), or μ (IgM), some of which may be further divided into subclasses, *e.g.*, $\gamma 1$ (IgG1), $\gamma 2$ (IgG2), $\gamma 3$ (IgG3), $\gamma 4$ (IgG4), $\alpha 1$ (IgA1) and $\alpha 2$ (IgA2). The light chain of an immunoglobulin may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the sequence of its constant domain. An immunoglobulin includes two Fab molecules and an Fc domain, linked via the immunoglobulin hinge region.

“Fab molecule” or “antigen binding fragment” is an antigen binding fragment of an antibody that includes the variable domain and constant domain of a light chain, and a variable domain and a CH1 domain of a heavy chain.

“Single chain variable domain” or “scFv” refers to an antigen binding moiety that includes variable regions of a heavy chain and light chain, which are linked by a linker peptide.

“Bispecific antibody,” refers to an artificial antibody with two different antigen binding sites. Bispecific antibody can refer to a full immunoglobulin protein with two different antigen binding sites, or can refer to other molecules having two antigen binding moieties, such as a fusion protein including two Fabs or two scFvs.

“Diabody” refers to a class of antigen binding molecules that are bivalent and bispecific. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) on the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.

“Bi-specific T-cell engager” refers to a class of bispecific antibodies having a first antigen binding moiety that binds to a T cell (*e.g.*, by binding CD3), and a second antigen binding moiety that binds a different antigen (*e.g.*, a tumor antigen).

“Nanobody” or “single domain antibody” refers to an antigen binding moiety that consists of a single monomeric variable antibody domain.

“Transferrin” is an iron transporter protein that may be used in a fusion protein to extend half-life. Human transferrin has a half-life of 12 days in serum.

“Cytokine” as used herein refers to a class of small (<25kDa) proteins that are involved in cell signaling and immunomodulation. Cytokines include, for example, IL2, interleukin-10 (IL-10), interleukin-1 (IL-1), interleukin-17 (IL-17), interleukin-18 (IL-18), interferon α , interferon β , interferon γ , TGF- β 1, TGF- β 2, and TGF- β 3, chemokine (C-C motif) ligand 2 (CCL2), and chemokine (C-C motif) ligand 19 (CCL19).

A “subject” according to any of the above embodiments is a mammal. Mammals include but are not limited to, domesticated animals (*e.g.*, cows, sheep, cats, dogs, and horses), primates (*e.g.*, human and non-human primates such as monkeys), rabbits, and rodents (*e.g.*, mice and rats). Preferably the subject is a human.

“Modulating an immune response” may include one or more of a general increase, an increase in T effector cell response (*e.g.*, cytotoxicity against tumor cells and virus infected cells), an increase in B cell activation, restoration of lymphocyte activation and proliferation, an increase in the expression of IL2 receptors, an increase in T cell responsiveness, an increase in natural killer cell activity or lymphokine-activated killer (LAK) cell activity, a decrease in regulatory T cells response to other T cells, and the like.

“Regulatory T cell” or “Treg cell” refers to a specialized type of CD4⁺ T cell that can function to suppress the responses of other T cells. Treg cells express the

α -subunit of the IL2 receptor (CD25) and the transcription factor forkhead box P3 (FOXP3) (Sakaguchi, *Annu Rev Immunol* 22, 531-62 (2004)), and are involved in the induction and maintenance of peripheral self-tolerance to antigens, including those expressed by tumors. Treg cells require IL2 for their function and development and
5 induction of their suppressive characteristics.

“T effector cells” refers to a population of T cells that respond to stimulus, such as IL2. T effector cells include CD8⁺ cytotoxic T cells and CD4⁺ helper T cells. As used herein, T effector cell does not include a T regulatory cell.

“Natural Killer cells” or “NK cells” are a component of the innate
10 immune system and are cytotoxic lymphocytes that play a major role in rejection of tumors and virus infected cells.

“Treatment,” “treating” or “ameliorating” refers to medical management of a condition, disease, or disorder of a subject (e.g., patient), which may be therapeutic, prophylactic/preventative, or a combination treatment thereof.

15 An “effective amount” or a “therapeutically effective amount” may refer to an amount of therapeutic agent (e.g., an engineered IL2 polypeptide or engineered IL2 fusion polypeptide described herein) that provides a desired physiological change, such as an anti-cancer effect. The desired physiological change may, for example, be a decrease in symptoms of a disease, or a decrease in severity of a disease, or may be a
20 reduction in the progression of a disease. With respect to cancer, the desired physiological changes may include, for example, tumor regression, a decreased rate of tumor progression, a reduced level of a cancer biomarker, reduced symptoms associated with cancer, a prevention or delay in metastasis, or clinical remission.

“Checkpoint inhibitor” refers to an agent that reduces the activity of an
25 immune checkpoint protein. A checkpoint inhibitor can be an antigen binding moiety that binds to and reduces activity of an immune checkpoint protein. Immune checkpoint proteins include, for example, programmed cell death protein 1 (PD-1 or CD279), programmed death-ligand 1 (PD-L1 or CD274), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4 or CD152), T-cell immunoglobulin mucin-3 (TIM3), Lymphocyte
30 Activating 3 (LAG3 or CD223), B7-H2 (ICOSL or CD275), and B7-H3 (CD276). Examples of checkpoint inhibitors includes ipilimumab (an anti-CTLA-4 antibody), nivolumab (an anti-PD-1 antibody), and pembrolizumab (an anti-PD-1 antibody).

“Cancer antigen” refers to a molecule that is preferentially expressed by cancer cells. Examples of cancer antigens include CD19, CD20, ROR1, fibroblast activation protein- α , and carcinoembryonic antigen (CEA).

“Oncolytic virus” refers to a virus that preferentially infects and kills cancer cells. For example oncolytic herpes viruses have been engineered to delete ICP34.5, resulting in a virus that only replicates in cancer (not healthy cells). An example of an oncolytic virus is Talimogene laherparepvec, which is used to treat melanoma.

“Cancer vaccine” refers to a vaccine that presents a cancer epitope to the immune system to elicit an anti-cancer response from the immune system. For example, sipuleucel-T is a vaccine for metastatic prostate cancer, which targets the immune response to the prostate cancer antigen prostatic acid phosphatase (PAP).

“Chimeric antigen receptors” or “CARs” are engineered antigen binding receptors that, when expressed in certain types of immune cells, activate the immune cell upon antigen binding. CARs typically include an extracellular domain comprising an antigen binding moiety (*e.g.*, an scFv), a transmembrane domain, and an intracellular immune signaling domain (*e.g.*, including signaling domains from CD3 ζ , 4-1BB, and/or CD28). CARs may be expressed, for example, by T cells or NK cells, and may include an antigen binding moiety that targets a cancer antigen, such as CD19 or ROR1.

“Tumor infiltrating lymphocyte” or “TIL” refers to a lymphocyte that is isolated from tumor tissue, manipulated *in vitro* (*e.g.*, stimulated using a cytokine such as interleukin-2), and then infused back into a patient so that the activating TIL returns to the tumor site and induces tumor regression.

“Tumor microenvironment inhibitor” refers to an agent that inhibits one or more conditions or cell types that promote tumor growth and are present in the local environment surrounding a tumor. For example, bevacizumab can inhibit the tumor microenvironment by reducing angiogenesis in a tumor microenvironment.

In the present description, the term “about” means $\pm 20\%$ of the indicated range, value, or structure, unless otherwise indicated. The term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. It should be understood that the terms “a” and “an” as used herein refer to “one or

more” of the enumerated components. The use of the alternative (*e.g.*, “or”) should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the terms “include” and “have” are used synonymously, which terms and variants thereof are intended to be construed as non-limiting. The term “comprise”

- 5 means the presence of the stated features, integers, steps, or components as referred to in the claims, but that it does not preclude the presence or addition of one or more other features, integers, steps, components, or groups thereof.

Recombinant DNA, molecular cloning, and gene expression techniques used in the present disclosure are known in the art and described in references, such as

10 Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory, New York, 2001, and Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD, 1999.

Engineered Interleukin-2 Polypeptide

As noted above, IL2 polypeptides of the present disclosure include

15 IL2R β agonists having an engineered IL2 receptor β (IL2R β) binding region 2. In some embodiments, the binding region 2 comprises:

X₁-X₂-X₃-D-X₄-X₅-X₆-N-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃ (SEQ ID NO: 1),

wherein X₁, X₃, X₆, X₈, X₁₂, and X₁₃ each comprise any residue,

wherein X₂, X₄, and X₁₀ are uncharged residues, and

- 20 wherein X₅, X₇, X₉, and X₁₁ each comprise uncharged, nonpolar residues.

For example, in some embodiments the engineered IL2 polypeptide has the amino acid sequence:

APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATEL

25 KHLQCLEEELKPLEEVLNLAQSKNFHLX₁X₂X₃DX₄X₅X₆NX₇X₈X₉X₁₀X₁₁X₁₂X₁₃L

KGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT (SEQ ID NO: 22),

wherein X₁, X₃, X₆, X₈, X₁₂, and X₁₃ each comprise any residue,

wherein X₂, X₄, and X₁₀ are uncharged residues, and

- 30 wherein X₅, X₇, X₉, and X₁₁ each comprise uncharged, nonpolar residues.

In certain embodiments, X₁ is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue. In some embodiments, X₁ is selected from C, T, G, W, I, S, E, and K. In some embodiments, X₁ is selected from G, K, E, C, and T. In certain embodiments, X₂ is an uncharged polar residue or an uncharged nonpolar residue. In some embodiments, X₂ is selected from Y, P, V, W, L, A, and G. In some
5 embodiments, X₂ is selected from V, P, W, and A. In certain embodiments, X₃ is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue. In some embodiments, X₃ is selected from S, T, Q, G, M, E, R, and K. In some embodiments, X₃ is selected from T, G, S, R, and E. In certain embodiments, X₄ is not
10 L. In some embodiments, X₄ is an uncharged nonpolar residue or an uncharged polar residue. In some embodiments, X₄ is selected from A, V, S, and T. In certain embodiments, X₅ is selected from I, L, T, and V. In some embodiments, X₅ is selected from I and V. In certain embodiments, X₆ is an uncharged polar residue, a basic residue, or an acidic residue. In some embodiments, X₆ is selected from S, T, E, D, and R. In
15 some embodiments, X₆ is selected from S, D, E, and T. In certain embodiments, X₇ is selected from I, A, M, and V. In some embodiments, X₇ is selected from I, A, and M. In certain embodiments, X₈ is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue. In some embodiments, X₈ is selected from S, T, N, Q, I, G, E, K, and R. In some embodiments, X₈ is selected from I, R, N, and T. In
20 certain embodiments, X₉ is selected from V, L, and I. In some embodiments, X₉ is V. In certain embodiments, X₁₀ is an uncharged polar residue or an uncharged nonpolar residue. In some embodiments, X₁₀ is selected from N, T, I, and L. In some embodiments, X₁₀ is selected from I and L. In certain embodiments, X₁₁ is selected from V, A, and I. In certain embodiments, X₁₂ is an uncharged polar residue, an
25 uncharged nonpolar residue, or an acidic residue. In some embodiments, X₁₂ is selected from Q, L, G, K, and R. In some embodiments, X₁₂ is selected from R, G, Q, and K. In certain embodiments, X₁₃ is an uncharged nonpolar residue or a basic residue. In some embodiments, X₁₃ is selected from A, D, and E. In some embodiments, X₁₃ is selected from E and A.

In some embodiments, the IL2R β binding region 2 is selected from:

- GVTDSISNAIVLARE (SEQ ID NO:2); KWGDAVSNARVLAGE (SEQ ID NO: 3);
 KWGDAVSNARVLAGA (SEQ ID NO:4); TLMDTTDNIGVLVRE (SEQ ID NO: 5);
 EPSDVISNINVLVQE (SEQ ID NO:6); SPQDSIENISVLVRE (SEQ ID NO: 7);
 5 WASDSIENITLLIQE (SEQ ID NO:8); CPTDTIENITVLIQE (SEQ ID NO: 9);
 RYKDSLENMQIIIQE (SEQ ID NO:10); TARDAVDNMRVIIQE (SEQ ID NO: 11);
 TPRDVVENNMNVLVLE (SEQ ID NO:12); TPSDVIENTMEVLILD (SEQ ID NO: 13);
 TPSDAIENINVLIRE (SEQ ID NO: 14); TPSDVIENTITVLVQE (SEQ ID NO:15);
 GVGDTIDNINVLVKE (SEQ ID NO: 16); IGRDSIDNIKVIVQE (SEQ ID NO:17);
 10 WATDTIRNVEVLVQE (SEQ ID NO: 18); TAEDVVTNITVLVQE (SEQ ID NO:19);
 TAEDVISNIRVNVQE (SEQ ID NO: 20); TPSDVIDNVSITVQE (SEQ ID NO:21);
 TARDAISNIRVIVQE (SEQ ID NO: 210); RARDAIDNIRVIVQE (SEQ ID NO: 211);
 TPRDAIDNINVIIQE (SEQ ID NO: 212); TPRDAIDNIRVIVQE (SEQ ID NO: 213);
 TPRDAIDNIRVIILE (SEQ ID NO: 214); TARDAISNINVIIQE (SEQ ID NO: 215);
 15 and TARDAIDNINVIVQE (SEQ ID NO: 216); and TARDAIDNIRVIVLE (SEQ ID
 NO: 217).

- In some embodiments, the engineered IL2R β binding region 2 is selected
 from: TPRDAIDNIRVIVQE (SEQ ID NO: 213); TPRDAIDNIRVIILE (SEQ ID
 NO:214); TARDAISNINVIIQE (SEQ ID NO: 215); and TARDAIDNINVIVQE (SEQ
 20 ID NO: 216).

- In some embodiments, the engineered IL2R β binding region 2 is selected
 from: GVTDSISNAIVLARE (SEQ ID NO:2); KWGDAVSNARVLAGA (SEQ ID
 NO:4); EPSDVISNINVLVQE (SEQ ID NO:6); CPTDTIENITVLIQE (SEQ ID NO: 9);
 TARDAVDNMRVIIQE (SEQ ID NO:11); GVGDTIDNINVLVKE (SEQ ID NO: 16);
 25 TAEDVVTNITVLVQE (SEQ ID NO:19).

In some embodiments, the engineered IL2R β binding region 2 is selected
 from: GVTDSISNAIVLARE (SEQ ID NO:2); CPTDTIENITVLIQE (SEQ ID NO: 9);
 and TARDAVDNMRVIIQE (SEQ ID NO:11).

In some embodiments, the engineered IL2 polypeptide has an amino acid sequence of SEQ ID NO: 22. In some embodiments, the engineered IL2 polypeptide has an amino acid sequence of any one of SEQ ID NOs: 23-42.

In some embodiments, the IL2R β agonists of the present disclosure include engineered IL2 polypeptides comprising a substitution to at least one residue selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94, relative to SEQ ID NO: 65. In certain embodiments, the at least one substitution is a substitution to residue L85. In certain embodiments, the IL2 polypeptide includes substitutions to at least two residues selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94. In some embodiments, the at least two residues are selected from R81, R83, L85, I92, and L94. In some embodiments, the IL2 polypeptide includes substitutions to at least three residues selected from R81, R83, L85, I92, and L94. In some embodiments, the engineered IL2 polypeptide includes substitutions to R81, R83, L85, I92, and L94. In some embodiments, the R81 substitution is selected from R81G, R81K, R81E, R81C, and R81T. In some embodiments, the R83 substitution is selected from R83T, R83G, R83S, and R83E. In some embodiments, the L85 substitution is selected from L85S, L85A, L85V, and L85T. In some embodiments, the I92 substitution is I92L. In some embodiments, the L94 substitution is selected from L94R, L94G, L94Q, and L94K. In some embodiments, the engineered IL2 polypeptide comprising a substitution to at least one residue selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94 has an IL2R β binding region 2 of any of SEQ ID NOs: 2-24.

In some embodiments, the engineered IL2 polypeptide has increased affinity for IL2R β as compared to the wild-type IL2. In certain embodiments, the binding of the engineered IL2 polypeptide to IL2R β has a K_D at least 10-fold greater, at least 15-fold greater, at least 20-fold greater, at least 25-fold greater, or at least 30-fold greater than binding of a wild-type IL2 to IL2R β . In some embodiments, the engineered IL2 polypeptide binds to IL2R β with a K_D at least 30-fold greater than a wild-type IL2. In some embodiments, the engineered IL2 polypeptide has at least a 10-fold increase, at least a 15-fold increase, at least a 20-fold increase, at least a 25-fold

increase, or at least a 30-fold increase in affinity for IL2R β as compared to wild-type IL2.

In some embodiments, the engineered IL2 polypeptide has a decrease in affinity for IL2R α as compared to wild-type IL2. In certain embodiments, the
5 engineered IL2 polypeptide has at least a 5% decrease, at least a 10% decrease, at least a 15% decrease, or at least a 20% decrease in affinity for IL2R α as compared to wild-type IL2.

In some embodiments, the engineered IL2 polypeptide has a similar affinity for IL2R α as compared to wild-type IL2. In certain embodiments, the
10 engineered IL2 polypeptide has an affinity for IL2R α that varies from the affinity of wild-type IL2 for IL2R α by no more than $\pm 20\%$, no more than $\pm 15\%$, no more than $\pm 10\%$, or no more than $\pm 5\%$.

Some embodiments of the present disclosure provide an engineered IL2 polypeptide comprising an engineered IL2 receptor α (IL2R α) binding region 1. The
15 engineered IL2R α binding region 1 can comprise a substitution selected from: a substitution at position K35, a substitution at R38, a substitution at F42, a substitution at Y45, or combinations thereof. In some embodiments, the engineered IL2 polypeptide binds to IL2R α with at least 2-fold reduced binding kinetics as compared to wild-type IL2.

20 In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position K35. In some embodiments, the substitution at position K35 comprises a non-basic residue. In some embodiments, the substitution at position K35 comprises an uncharged residue or an acidic residue. In some embodiments, the substitution at position K35 is selected from: K35G, K35L, K35S, K35V, K35D, K35E,
25 and K35C.

In some embodiments, the engineered IL2 polypeptide comprises a substitution at position R38. In some embodiments, the substitution at position R38 comprises a non-basic residue. In some embodiments, the substitution at position R38 comprises an uncharged residue or an acidic residue. In some embodiments, the

substitution at position R38 is selected from: R38V, R38D, R38E, R38S, R38I, R38A, R38Y, R38G, R38C, and R38N.

In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position F42. In some embodiments, the substitution at position F42
5 comprises an uncharged residue. In some embodiments, the substitution at position F42 comprises a basic residue. In some embodiments, the substitution at position F42 is selected from: F42A, F42R, F42G, F42I, F42L, F42P and F42H.

In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position Y45. In some embodiments, the substitution at position Y45
10 comprises an uncharged residue. In some embodiments, the substitution at position Y45 comprises an uncharged polar residue or an uncharged non-polar residue. In some embodiments, the Y45 substitution is Y45S, Y45P, Y45A, Y45V, Y45C, Y45T, and Y45F.

In some embodiments, the engineered IL2 polypeptide may comprise a
15 substitution at position K35 and a substitution at position R38. In some embodiments, the engineered IL2 polypeptide comprises a K35G substitution and R38E substitution.

In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position K35 and a substitution at position F42. In some embodiments, the engineered IL2 polypeptide comprises a K35S substitution and an F42G
20 substitution.

In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position K35, a substitution at position R38, and a substitution at position F42. In some embodiments, the engineered IL2 polypeptide comprises a K35L substitution, an R38D substitution, and an F42R substitution.

25 In some embodiments, the engineered IL2 polypeptide may comprise a substitution at position R38 and a substitution at position Y45S. In some embodiments, the engineered IL2 polypeptide comprises an R38D substitution and an Y45S substitution. In some embodiments, the engineered IL2 polypeptide comprises an R38V substitution and an Y45S substitution.

In some embodiments, the engineered IL2 polypeptide binds to IL2R α with at least 10-fold reduced binding kinetics as compared to wild-type IL2.

In some embodiments, the IL2R α binding region 1 is selected from:

- PVLTRMLTIKFY (SEQ ID NO: 183); PKLTRMLTLKFP (SEQ ID NO:184);
 5 PDLTSMLAFKFY (SEQ ID NO:185); PGLTEMLTFKFY (SEQ ID NO:186);
 PSLTRMLTGKFY (SEQ ID NO:187); PELTIMLTPKFY (SEQ ID NO:188);
 PCLTAMLTALKFA (SEQ ID NO:189); PCLTAMLTALKFA (SEQ ID NO:190);
 PKLTRMLTHKFV (SEQ ID NO:191); PCLTDMLTFKFY (SEQ ID NO:192);
 PLLTDMLTRKFY (SEQ ID NO:193); PLLTDMLTFKFY (SEQ ID NO:194);
 10 PKLTDMLTFKFS (SEQ ID NO:195); PKLTYMLTRKFY (SEQ ID NO:196);
 PKLTRMLTFKFC (SEQ ID NO:197); PKLTSMLTFKFS (SEQ ID NO:198);
 PKLTSMLTFKFS (SEQ ID NO:199); PKLTYMLTFKFS (SEQ ID NO:200);
 PKLTYMLTFKFS (SEQ ID NO:201); PKLTGMLTFKFS (SEQ ID NO:202);
 PKLTVMLTFKFT (SEQ ID NO:203); PKLTVMLTFKFS (SEQ ID NO:204);
 15 PKLTVMLTFKFP (SEQ ID NO:205); PKLTVMLTFKFF (SEQ ID NO:206);
 PKLTCMLTFKFA (SEQ ID NO:207); PKLTNMLTFKFA (SEQ ID NO:208); and
 PKLTNMLTFKFS (SEQ ID NO:209).

- In some embodiments, the engineered IL2 polypeptide shares at least 80%, for example, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at
 20 least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity
 with the residues outside of the IL2R β binding region 2 (*i.e.*, residues 1-80 and 96-133)
 of SEQ ID NO: 22 and binds to IL2R β . In some embodiments, the engineered IL2
 polypeptide shares at least 80%, for example, at least 85%, at least 88%, at least 90%, at
 least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least
 25 100% sequence identity with the residues outside of the IL2R α binding region 1 (*i.e.*,
 residues 1-33 and 46-133) of SEQ ID NO: 223 and has reduced binding to IL2R α and
 binds to IL2R β . In some embodiments, the engineered IL2 polypeptide shares at least
 80%, for example, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at
 least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity
 30 with the residues outside of the IL2R α binding region 1 and IL2R β binding region 2

(*i.e.*, residues 1-33, 46-80, 96-133) of SEQ ID NO: 22 or SEQ ID NO: 223 and has reduced binding to IL2R α and binds to IL2R β . In some embodiments, the present disclosure provides an engineered IL2 polypeptide including an engineered IL2R β binding region 2 as previously described and an engineered IL2R α binding region 1 as previously described. In certain embodiments, the engineered IL2 polypeptide comprises an engineered IL2R α binding region 1 selected from PVLTRMLTIKFY (SEQ ID NO: 183); PKLTRMLTLKFP (SEQ ID NO:184); PDLTSMLAFKFY (SEQ ID NO:185); PGLTEMLTFKFY (SEQ ID NO:186); PSLTRMLTGKFY (SEQ ID NO:187); PELTIMLTPKFY (SEQ ID NO:188); PCLTAMLTALKFA (SEQ ID NO:189); PCLTAMLTALKFA (SEQ ID NO:190); PKLTRMLTHKFV (SEQ ID NO:191); PCLTDMLTFKFY (SEQ ID NO:192); PLLTDMLTRKFY (SEQ ID NO:193); PLLTDMLTFKFY (SEQ ID NO:194); PKLTDMLTFKFS (SEQ ID NO:195); PKLTYMLTRKFY (SEQ ID NO:196); PKLTRMLTFKFC (SEQ ID NO:197); PKLTSMLTFKFS (SEQ ID NO:198); PKLTSMLTFKFS (SEQ ID NO:199); PKLTYMLTFKFS (SEQ ID NO:200); PKLTYMLTFKFS (SEQ ID NO:201); PKLTGMLTFKFS (SEQ ID NO:202); PKLTVMLTFKFT (SEQ ID NO:203); PKLTVMLTFKFS (SEQ ID NO:204); PKLTVMLTFKFP (SEQ ID NO:205); PKLTVMLTFKFF (SEQ ID NO:206); PKLTCMLTFKFA (SEQ ID NO:207); PKLTNMLTFKFA (SEQ ID NO:208); and PKLTNMLTFKFS (SEQ ID NO:209); and comprises an engineered IL2R β binding region 2 is selected from: GVTDSISNAIVLARE (SEQ ID NO: 2); KWGDAVSNARVLAGE (SEQ ID NO: 3); KWGDAVSNARVLAGE (SEQ ID NO: 4); TLMDDTDNIGVLVRE (SEQ ID NO: 5); EPSDVISNINVLVQE (SEQ ID NO: 6); SPQDSIENISVLVRE (SEQ ID NO: 7); WASDSIENITLLIQE (SEQ ID NO: 8); CPTDTIENITVLIQE (SEQ ID NO: 9); RYKDSLENMQIIQE (SEQ ID NO: 10); TARDAVDNMRVIIQE (SEQ ID NO: 11); TPRDVVENMNVLVLE (SEQ ID NO: 12); TPSDVIENTMEVLILD (SEQ ID NO: 13); TPSDAIENINVLIRE (SEQ ID NO: 14); TPSDVIENTITVLVQE (SEQ ID NO: 15); GVGDTIDNINVLVKE (SEQ ID NO: 16); IGRDSIDNIKVIVQE (SEQ ID NO: 17); WATDTIRNVEVLVQE (SEQ ID NO: 18); TAEDVVTNITVLVQE (SEQ ID NO: 19); TAEDVISNIRVNVQE (SEQ ID NO: 20); TPSDVIDNVSITVQE (SEQ ID NO: 21);

TARDAISNIRVIVQE (SEQ ID NO: 210); RARDAIDNIRVIVQE (SEQ ID NO: 211);
 TPRDAIDNINVIIQE (SEQ ID NO: 212); TPRDAIDNIRVIVQE (SEQ ID NO: 213);
 TPRDAIDNIRVIILE (SEQ ID NO: 214); TARDAISNINVIIQE (SEQ ID NO: 215);
 and TARDAIDNINVIVQE (SEQ ID NO: 216); and TARDAIDNIRVIVLE (SEQ ID
 5 NO: 217).

In particular embodiments, the engineered IL2 polypeptide includes an
 engineered IL2R β binding region 2 selected from GVTDSISNAIVLARE (SEQ ID NO:
 2); TARDAVDNMRVIIQE (SEQ ID NO: 11); TPRDAIDNIRVIVQE (SEQ ID NO:
 213); TPRDAIDNIRVIILE (SEQ ID NO: 214); TARDAISNINVIIQE (SEQ ID NO:
 10 215); and TARDAIDNINVIVQE (SEQ ID NO: 216); and an engineered IL2R α binding
 region 1 as previously described.

In some embodiments, the engineered IL2 polypeptide is selected from
 any one of SEQ ID NOs: 147-170, with the C-terminal histidine tag optionally included
 (or excluded). In some embodiments, the C-terminal histidine tag is replaced another
 15 linker, such as a gly-ser linker.

Engineered IL2 fusion polypeptides

Some embodiments of the present disclosure provide engineered IL2
 fusion polypeptides. The engineered IL2 fusion polypeptide may include an engineered
 IL2 polypeptide as previously described herein, and at least one additional molecule
 20 covalently attached to the engineered IL2 polypeptide via a peptide bond or other
 chemical linkage. In some embodiments, the at least one additional molecule of the
 fusion polypeptide is a half-life extending molecule. In some embodiments, the half-life
 extending molecule comprises a half-life extending polypeptide. In some embodiments,
 the half-life extending polypeptide comprises an Fc domain, human serum albumin
 25 (HSA), an HSA binding molecule, or transferrin.

In certain embodiments, the IL2 fusion polypeptide comprises an Fc
 domain. In some embodiments, the Fc domain is derived from an IgG antibody.
 Human IgG antibodies have several subclasses, including, but not limited to IgG1,
 IgG2, IgG3, and IgG4. In particular embodiments, the Fc domain is derived from an
 30 IgG1 antibody or an IgG4 antibody. In some embodiments, the Fc domain has one or

more substitutions that reduce effector function of the Fc domain. Examples of substitutions that reduce Fc effector function include L34A, L235A, and P329G.

“LALAPG” may refer to a modified Fc domain including each of L34A, L235A, and P329G. In some embodiments, the Fc domain comprises at least one amino acid residue
5 modification to increase serum half-life. Representative modifications to the Fc domain are described in US Patent No. 7,317,091; US Patent No. 8,735,545; US Patent No. 7,371,826; US Patent No. 7,670,600; and US 9,803,023. In some embodiments, the Fc domain is SEQ ID NO: 64. In some embodiments, the engineered IL2-Fc fusion polypeptide comprises a sequence selected from SEQ ID NOs: 39-49.

10 In some embodiments, the at least one additional molecule of the fusion polypeptide is an antigen binding moiety. In some embodiments, the antigen binding moiety comprises an immunoglobulin, a Fab molecule, an scFv, a bi-specific T-cell engager, a diabody, a single domain antibody, or a nanobody. An antigen binding moiety may bind, for example, carcinoembryonic antigen (CEA), GD2, or CD20. An
15 example of a CEA antigen moiety is CH1A1A-2F. An example of a GD-2 antigen binding moiety is dinutuximab, and an example of a CD20 antigen binding moiety is rituximab.

In some embodiments, the at least one additional molecule of the fusion polypeptide is a cytokine. In some embodiments, the cytokine is selected from
20 interleukin-2, interleukin-15, interleukin-7, interleukin-10, and C-C motif chemokine ligand 19 (CCL19). In some embodiments, the additional molecule of the fusion polypeptide is a second engineered IL2 polypeptide as described herein.

In some embodiments, the half-life extending molecule comprises polyethylene glycol (PEG) or polypropylene glycol (PPG).

25 In some embodiments, the fusion polypeptide is a monovalent fusion polypeptide. A monovalent fusion polypeptide refers to a fusion polypeptide that has one copy of an engineered IL2 polypeptide.

In certain embodiments, the monovalent fusion polypeptide includes an engineered IL2 polypeptide linked to a fusion partner, such as an Fc region. A variety
30 of linkers are known in the art and may be used to covalently link an engineered IL2

described herein to a fusion partner, such as an Fc region. By “linker”, “linker sequence”, herein is meant a molecule or group of molecules (such as a monomer or polymer) that connects two molecules and often serves to place the two molecules in a preferred configuration. The linker may contain amino acid residues that provide flexibility. Thus, the linker peptide may predominantly include the following amino acid residues: Gly, Ser, Ala, or Thr. The linker peptide should have a length that is adequate to link two molecules in such a way that they assume the correct conformation relative to one another so that they retain the desired activity. Suitable lengths for this purpose include at least one and not more than 30 amino acid residues. Preferably, the linker is from about 1 to 30 amino acids in length, with linkers of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 19 and 20 amino acids in length being preferred. Useful linkers include glycine-serine polymers (including, for example, (GS)_n, (GSGGS)_n (SEQ ID NO:218), (GGGGS)_n (SEQ ID NO:219) and (GGGS)_n (SEQ ID NO:220), where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers. In some embodiments, the fusion polypeptide is a bivalent fusion polypeptide. A bivalent fusion protein may refer to a molecular complex that includes two copies of engineered IL2 polypeptides, which may be of the same sequence or different sequences. The molecular complex may be bound non-covalently. For example, a bivalent fusion protein may include two Fc regions bound together non-covalently such as by one or more disulfide bridges, or by knobs-into-holes chemistry.

Methods of Making Engineered IL2 Polypeptides

Engineered IL2 polypeptides or engineered IL2 fusion polypeptides can be prepared by genetic or chemical methods well known in the art and by the methods disclosed in the Examples below. Genetic methods may include, for example, site-specific mutagenesis of the DNA sequence encoding the polypeptide, PCR, and gene synthesis. The intended nucleotide changes can be verified by sequencing. The nucleotide sequence of native IL2 has been described by Taniguchi et al. (Nature 302, 305-10 (1983)) and a nucleic acid encoding native human IL2 is available from, for example, American Type Culture Collection (Rockville Md.).

Engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be obtained, for example, by recombinant production or solid-state peptide synthesis. For recombinant production, a polynucleotide encoding an engineered IL2 polypeptide or engineered IL2 fusion polypeptide can be isolated and inserted into one or more

5 vectors for cloning and/or expression in a host cell. Such polynucleotides may be readily isolated and sequenced by conventional procedures. In certain embodiments, a vector, such as an expression vector, comprising one or more of the polynucleotides of the instant disclosure is provided. Methods which are well known to those skilled in the art can be used to construct expression vectors containing the coding sequence

10 engineered IL2 polypeptide or engineered IL2 fusion polypeptide along with appropriate transcriptional/translational control signals. These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL (FOURTH EDITION),

15 Cold Spring Harbor Laboratory, N.Y. (2012); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, N.Y (1993). The expression vector can be part of a plasmid, virus, or may be a nucleic acid fragment. The expression vector includes an expression cassette into which the polynucleotide encoding engineered IL2 polypeptide

20 or engineered IL2 fusion polypeptide (*i.e.* the coding region) is cloned in operable association with a promoter and/or other transcription or translation control elements. As used herein, a “coding region” is a portion of nucleic acid which consists of codons translated into amino acids. Although a “stop codon” (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, if

25 present, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, 5' and 3' untranslated regions, and the like, are not part of a coding region. Two or more coding regions can be present in a single polynucleotide construct, *e.g.*, on a single vector, or in separate polynucleotide constructs, *e.g.*, on separate (different) vectors. Furthermore, any vector may contain a

30 single coding region, or may comprise two or more coding regions, *e.g.*, a vector of the

disclosed herein may encode one or more polypeptides, which are post- or co-translationally separated into the final proteins via proteolytic cleavage. In addition, a vector, polynucleotide, or nucleic acid of the instant disclosure may encode heterologous coding regions, either fused or unfused to a first or second polynucleotide encoding the polypeptides disclosed herein, or variant or derivative thereof.

Heterologous coding regions include without limitation specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain. An operable association is when a coding region for a gene product, *e.g.*, a polypeptide, is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s). Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are “operably associated” if induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the nature of the linkage between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to direct the expression of the gene product or interfere with the ability of the DNA template to be transcribed. Thus, a promoter region would be operably associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting transcription of that nucleic acid. The promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells. Other transcription control elements, besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription. Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art. These include, without limitation, transcription control regions, which function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegaloviruses (*e.g.*, the immediate early promoter, in conjunction with intron-A), simian virus 40 (*e.g.*, the early promoter), and retroviruses (*e.g.*, Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone and rabbit β -globin, as well as other sequences capable of controlling gene

expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers as well as inducible promoters (*e.g.*, promoters inducible tetracyclins). Similarly, a variety of translation control elements are known to those of ordinary skill in the art. These include, but are not limited to ribosome binding
5 sites, translation initiation and termination codons, and elements derived from viral systems (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence). The expression cassette may also include other features such as an origin of replication, and/or chromosome integration elements such as retroviral long terminal repeats (LTRs), or adeno-associated viral (AAV) inverted terminal repeats (ITRs).

10 Polynucleotide and nucleic acid coding regions of the present disclosure may be associated with additional coding regions that encode secretory or signal peptides, which direct the secretion of a polypeptide encoded by a polynucleotide of the present disclosure. For example, if secretion of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide is desired, DNA encoding a signal sequence may be
15 placed upstream of the nucleic acid encoding the mature amino acids of the an engineered IL2 polypeptide or engineered IL2 fusion polypeptide. Those of ordinary skill in the art are aware that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the translated polypeptide to produce a secreted or “mature” form of the polypeptide. For
20 example, native human IL2 is translated with a 20 amino acid signal sequence at the N-terminus of the polypeptide, which is subsequently cleaved off to produce mature, 133 amino acid human IL2. In some embodiments, the native signal peptide, *e.g.* the IL2 signal peptide or an immunoglobulin heavy chain or light chain signal peptide is used, or a functional derivative of that sequence that retains the ability to direct the secretion
25 of the polypeptide that is operably associated with it.

In some embodiments, a polynucleotide encoding the engineered IL2 polypeptide or engineered IL2 fusion polypeptide further includes a DNA sequence encoding a sequence to facilitate purification (*e.g.*, a histidine tag) or for labeling the engineered IL2 polypeptide or engineered IL2 fusion polypeptide within or at the ends

of the polynucleotide encoding the engineered IL2 polypeptide or engineered IL2 fusion polypeptide.

In certain embodiments, a host cell comprising one or more polynucleotides encoding an engineered IL2 polypeptide or engineered IL2 fusion polypeptide is provided. In certain embodiments, the host cell comprises one or more vectors encoding the engineered IL2 polypeptide or engineered IL2 fusion. The host cell can be any kind of cellular system that can be used to generate the engineered IL2 polypeptide or engineered IL2 fusion polypeptide. Such cells may be transfected or transduced as appropriate with the particular expression vector encoding the engineered IL2 polypeptide or engineered IL2 fusion, and large quantities of vector containing cells can be grown for seeding large scale fermenters to obtain sufficient quantities of encoding the engineered IL2 polypeptide or engineered IL2 fusion for clinical applications. Suitable host cells include prokaryotic microorganisms, such as *E. coli*, or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, or the like. For example, polypeptides may be produced in bacteria in particular when glycosylation is not needed. After expression, the polypeptide may be isolated from the bacterial cell in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of a polypeptide with a partially or fully human glycosylation pattern. Suitable host cells for the expression of (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of *Spodoptera frugiperda* cells. Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants). Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian

host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293T cells as described, *e.g.*, in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse sertoli cells (TM4 cells as described, *e.g.*, in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described, *e.g.*, in Mather et al., Annals N.Y. Acad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr⁻ CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63 and Sp2/0. For a review of certain mammalian host cell lines suitable for protein production, see, *e.g.*, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003). Host cells include cultured cells, *e.g.*, mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell, a human embryonic kidney (HEK) cell or lymphoid cell (*e.g.*, YO, NS0, Sp20 cell).

Standard technologies are known in the art to express foreign genes in these systems. Cells expressing an engineered IL2 polypeptide fused to either the heavy or the light chain of an antigen binding moiety, such as an antibody, may be engineered so as to also express the other of the antibody chains such that the expressed engineered IL2 fusion polypeptide comprises an antibody that has both a heavy and a light chain.

In some embodiments, a method of producing an engineered IL2 polypeptide or engineered IL2 fusion polypeptide is provided. In some embodiments, the method comprises culturing a host cell comprising a polynucleotide encoding the an engineered IL2 polypeptide or engineered IL2 fusion polypeptide, as provided herein, under conditions suitable for expression of the an engineered IL2 polypeptide or engineered IL2 fusion polypeptide, and optionally recovering and/or purifying the an

engineered IL2 polypeptide or engineered IL2 fusion polypeptide from the host cell (or host cell culture medium, for example, if the host cell secretes the polypeptide).

Pharmaceutical Compositions

Provided herein are pharmaceutical compositions comprising an engineered IL2 polypeptide or engineered IL2 fusion polypeptide as described herein and a pharmaceutically acceptable diluent(s), excipient(s), or carrier(s). In some embodiments, the pharmaceutical compositions comprise an engineered IL2 polypeptide or an engineered IL2 fusion polypeptide as disclosed herein and an additional therapeutic agent (e.g., combination therapy). Non-limiting examples of such therapeutic agents are described herein below. The pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the engineered IL2 or IL2 fusion polypeptide into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any pharmaceutically acceptable techniques, carriers, and excipients are used as suitable to formulate the pharmaceutical compositions described herein: Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999). Examples of IL-2 compositions are described in U.S. Pat. Nos. 4,604,377 and 4,766,106, which are incorporated by reference herein.

As used herein, "pharmaceutically acceptable carrier" and "physiologically acceptable carriers" are used interchangeably and include any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g. antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, antioxidants, proteins, drugs, drug stabilizers, polymers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one

of ordinary skill in the art and are molecular entities and compositions that are generally non-toxic to recipients at the dosages and concentrations employed, *i.e.*, do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate (*see*, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein
 5 by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.

The pharmaceutical composition may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form,
 10 and whether it need to be sterile for such routes of administration as injection. Engineered IL2 polypeptides or engineered IL2 fusion polypeptides as describe herein (and any additional therapeutic agent) can be administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrasplenically, intrarenally, intrapleurally, intratracheally,
 15 intranasally, intravitreally, intravaginally, intrarectally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, by inhalation (e.g. aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid
 20 compositions (e.g. liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference). Parenteral administration, in particular intravenous injection, is most commonly used for administering polypeptide molecules such as the engineered IL2
 25 polypeptides or engineered IL2 fusion polypeptides describe herein.

Parenteral compositions include those designed for administration by injection, e.g. subcutaneous, intradermal, intralesional, intravenous, intraarterial intramuscular, intrathecal or intraperitoneal injection. For injection, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein may be formulated
 30 in aqueous solutions, preferably in physiologically compatible buffers such as Hanks'

solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Alternatively, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free

5 water, before use. Sterile injectable solutions are prepared by incorporating the engineered IL2 polypeptides or engineered IL2 fusion polypeptides in the required amount in the appropriate solvent with various of the other ingredients enumerated below, as required. Sterility may be readily accomplished, *e.g.*, by filtration through sterile filtration membranes. Generally, dispersions are prepared by incorporating the

10 various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsion, methods of preparation include vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-

15 filtered liquid medium thereof. The liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic prior to injection with sufficient saline or glucose. The pharmaceutical composition is preferably stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin

20 contamination should be kept minimally at a safe level, for example, less than 0.5 ng/mg protein. Suitable pharmaceutically acceptable carriers include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium

25 chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine;

30 monosaccharides, disaccharides, and other carbohydrates including glucose, mannose,

or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, dextran, or the like. In some embodiments, the suspension may also contain suitable stabilizers or agents, which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleates or triglycerides, or liposomes.

In some embodiments, aqueous suspensions contain one or more polymers as suspending agents. Example polymers include water-soluble polymers such as cellulosic polymers, *e.g.*, hydroxypropyl methylcellulose, and water-insoluble polymers such as cross-linked carboxyl-containing polymers. Certain pharmaceutical compositions described herein comprise a mucoadhesive polymer, selected for example from carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.

In some embodiments, the pharmaceutical compositions include solubilizing agents to aid in the solubility of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide. The term "solubilizing agent" generally includes agents that result in formation of a micellar solution or a true solution of the agent. Certain acceptable nonionic surfactants, for example polysorbate 80, are useful as solubilizing agents. Examples include glycols, polyglycols, *e.g.*, polyethylene glycol 400, and glycol ethers.

In some embodiments, the pharmaceutical compositions include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and

tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.

5 In some embodiments, the pharmaceutical compositions include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.

10 In some embodiments, the pharmaceutical compositions include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.

15 In some embodiments, the pharmaceutical compositions include one or more surfactants to enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, *e.g.*, polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, *e.g.*, octoxynol 10, octoxynol 40.

20 In some embodiments, the pharmaceutical compositions include one or more antioxidants to enhance chemical stability where required. Suitable antioxidants include, by way of example only, ascorbic acid and sodium metabisulfite.

In certain embodiments, aqueous suspension compositions are packaged in single-dose non-reclosable containers. Alternatively, multiple-dose reclosable
25 containers are used, in which case it is typical to include a preservative in the composition.

In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein are delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the
30 therapeutic agent. Various sustained-release materials are useful herein. In some

embodiments, sustained-release capsules release the engineered IL2 polypeptide or engineered IL2 fusion polypeptides for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization are employed. Examples of sustained-release
5 preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, *e.g.* films, or microcapsules. In some embodiments, prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations
10 thereof.

In some embodiments, engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate)
15 microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990).

In some embodiments, engineered IL2 polypeptides or engineered IL2
20 fusion polypeptides described herein may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be formulated with suitable polymeric or hydrophobic materials (for example as an
25 emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Pharmaceutical compositions comprising the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein may be manufactured by means of conventional mixing, dissolving, emulsifying, encapsulating,
30 entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated

in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

5 In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be formulated into a composition in a free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or base. These include the acid addition salts, *e.g.*, those formed with the free amino groups of a proteinaceous composition, or which are
10 formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutical salts tend to be
15 more soluble in aqueous and other protic solvents than are the corresponding free base forms.

 In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described herein are formulated for oral administration. In various embodiments, the engineered IL2 polypeptides or engineered IL2 fusion
20 polypeptides described herein are formulated in oral dosage forms that include, by way of example only, tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like.

 In certain embodiments, pharmaceutical preparations for oral use are obtained by mixing one or more solid excipient with one or more of the engineered IL2
25 polypeptides or engineered IL2 fusion polypeptides described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch,
30 potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose,

hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as:
polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. In specific
embodiments, disintegrating agents are optionally added. Disintegrating agents include,
by way of example only, cross-linked croscarmellose sodium, polyvinylpyrrolidone,
5 agar, or alginic acid or a salt thereof such as sodium alginate.

In some embodiments, dosage forms, such as dragee cores and tablets,
are provided with one or more suitable coating. In specific embodiments, concentrated
sugar solutions are used for coating the dosage form. The sugar solution, optionally
contain additional components, such as by way of example only, gum arabic, talc,
10 polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide,
lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs and/or
pigments are also optionally added to the coatings for identification purposes.
Additionally, the dyestuffs and/or pigments are optionally utilized to characterize
different combinations of active agent doses.

15 In certain embodiments, therapeutically effective amounts of at least one
of the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described
herein are formulated into other oral dosage forms. Oral dosage forms include push-fit
capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a
plasticizer, such as glycerol or sorbitol. In specific embodiments, push-fit capsules
20 contain the active ingredients in admixture with one or more filler. Fillers include
lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate
and, optionally, stabilizers. In some embodiments, soft capsules contain one or more
active agent that is dissolved or suspended in a suitable liquid. Suitable liquids may
include one or more fatty oil, liquid paraffin, or liquid polyethylene glycol. In addition,
25 stabilizers are optionally added.

In some embodiments, therapeutically effective amounts of at least one
of the engineered IL2 polypeptides or engineered IL2 fusion polypeptides described
herein are formulated for buccal or sublingual administration. Formulations suitable for
buccal or sublingual administration include, by way of example only, tablets, lozenges,
30 or gels.

In some embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptide is administered topically. The engineered IL2 polypeptide or engineered IL2 fusion polypeptide described herein are formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, 5 pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical compositions optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides are formulated for transdermal administration. In specific 10 embodiments, transdermal formulations employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. In various embodiments, such patches are constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. In additional embodiments, the transdermal delivery 15 of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide is accomplished by means of iontophoretic patches and the like. In certain embodiments, transdermal patches provide controlled delivery of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide. In specific embodiments, the rate of absorption is slowed by using rate-controlling membranes or by trapping the engineered IL2 20 polypeptide or engineered IL2 fusion polypeptide within a polymer matrix or gel. In alternative embodiments, absorption enhancers are used to increase absorption. Absorption enhancers or carriers include absorbable pharmaceutically acceptable solvents that assist passage through the skin. For example, in one embodiment, transdermal devices are in the form of a bandage comprising a backing member, a 25 reservoir containing the engineered IL2 polypeptide or engineered IL2 fusion polypeptide optionally with carriers, optionally a rate controlling barrier to deliver the engineered IL2 polypeptide or engineered IL2 fusion polypeptide to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

In some embodiments, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides are formulated for administration by inhalation. Various forms suitable for administration by inhalation include, but are not limited to, aerosols, mists or powders. Pharmaceutical compositions of the engineered IL2 polypeptides or engineered IL2 fusion polypeptides may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant (*e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In specific embodiments, the dosage unit of a pressurized aerosol is determined by providing a valve to deliver a metered amount. In certain embodiments, capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator is formulated containing a powder mix of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide and a suitable powder base such as lactose or starch.

In some embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptides are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.

In certain embodiments, the formulations described herein comprise one or more antioxidants, metal chelating agents, thiol containing compounds and/or other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (l) pentosan polysulfate and

other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.

In some embodiments, the concentration of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w/w, w/v or v/v.

In some embodiments, the concentration of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25%, 18%, 17.75%, 17.50%, 17.25%, 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25%, 15%, 14.75%, 14.50%, 14.25%, 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25%, 11%, 10.75%, 10.50%, 10.25%, 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25%, 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 1.25%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w/w, w/v, or v/v.

In some embodiments, the concentration of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40 %, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately

27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v.

In some embodiments, the concentration of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v.

In some embodiments, the amount the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g.

In some embodiments, the amount of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g,

0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, , 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5 g, 7 g, 7.5 g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g.

In some embodiments, the amount of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide provided in the pharmaceutical compositions of the present disclosure is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.

10 Methods of Treatment and Use

In some embodiments of the present disclosure provided herein are methods of modulating an immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide, an engineered IL2 fusion polypeptide, or a pharmaceutical composition thereof as previously described herein. In certain embodiments, modulating the immune response includes at least one of: enhancing effector T cell activity, enhancing NK cell activity, and suppressing regulatory T cell activity. In some embodiments of the present disclosure provided herein engineered IL2 polypeptides as previously described, fusion polypeptides as previously described, and/or pharmaceutical compositions as previously described, for use in a method of modulating an immune response in a subject in need thereof. In some embodiments, modulating the immune response comprising increasing STAT5 phosphorylation compared to WT IL2.

In some embodiments of the present disclosure is a method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide, an engineered IL2 fusion polypeptide, or a pharmaceutical composition thereof as previously described herein. In some embodiments of the present disclosure provided herein engineered IL2 polypeptides as previously described, fusion polypeptides as previously described, and/or pharmaceutical compositions as previously described, for use in a method of treating a subject for a disease. Non-limiting examples of diseases or

condition contemplated in the method include proliferative disorders, such as cancer, and immunosuppression.

In some embodiments, is a method of treating a proliferative disorder comprising administering to the subject a therapeutically effective amount of an engineered IL2 polypeptide, an engineered IL2 fusion polypeptide, or a pharmaceutical composition thereof as previously described herein. In some embodiments, the proliferative disorder is cancer. Non-limiting examples of cancers include bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, glioblastoma, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, skin cancer, melanoma, bone cancer, renal cell carcinoma, and kidney cancer. Also included are pre-cancerous conditions or lesions and cancer metastases. Other cell proliferation disorders include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic region, and urogenital system. Similarly, other cell proliferation disorders can also be treated, such as hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other cell proliferation disease, besides neoplasia, located in an organ system listed above.

In some embodiments, the method of treatment or modulating the immune response further comprises administering to the subject a therapeutically effective amount of at least one additional therapeutic agent (*e.g.*, a combination therapy). In certain embodiments, the additional therapeutic agent is an anti-cancer agent. Examples of anti-cancer agents include checkpoint inhibitors (*e.g.*, anti-PD1 antibodies), chemotherapeutic agents, agents that inhibit a tumor microenvironment, cancer vaccines (*e.g.*, Sipuleucel-T), oncolytic viruses (*e.g.*, talimogene laherparepvec), immune cells expressing a chimeric antigen receptor, and tumor infiltrating lymphocytes. In certain embodiments, the additional therapeutic agent is a molecule including an antigen binding moiety. In certain specific embodiments, the antigen

binding moiety is selected from a single domain antibody, a Fab molecule, an scFv, a diabody, a nanobody, a bi-specific T cell engager, or an immunoglobulin. In certain embodiments, the antigen binding moiety is specific to a tumor antigen (*e.g.*, carcinoembryonic antigen, fibroblast activation protein- α , CD20) or a check point protein (*e.g.*, CTLA-4, PD-1 or PD-L1). In some embodiments, the additional therapeutic agent comprises an immune cell expressing a chimeric antigen receptor, an immune cell expressing an engineered T cell receptor, or a tumor infiltrating lymphocyte. In certain embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptide may be encoded by a polynucleotide transfected, transduced, or otherwise introduced into the immune cell that expresses the chimeric antigen receptor, the immune cell expressing an engineered T cell receptor, or the tumor infiltrating lymphocyte. In such embodiments, the immune cell may be an armored chimeric antigen receptor-expressing cell. The polynucleotide may additionally encode a secretion signal (*e.g.*, the native IL2 signal sequence or a signal sequence derived from another protein) directly upstream of the engineered IL2 polypeptide coding sequence, to allow the cell to secrete the engineered IL2 polypeptide or engineered IL2 fusion polypeptide.

In some embodiments, the methods of treatment or modulating the immune response include administering to the subject an engineered IL2 polypeptide having an IL2R β binding region two of SEQ ID NO: 1. In certain embodiments, the methods of treatment or modulating the immune response include administering to the subject an engineered IL2 polypeptide having an IL2R β binding region two of any one of SEQ ID NOs: 2-21. In certain embodiments, the method includes administering to the subject an engineered IL2 polypeptide of any of SEQ ID NOs: 23-42, any one of SEQ ID NOs: 44-63, any one of SEQ ID NOs: 147-170 (with the C-terminal histidine tag optionally included), or an Fc fusion polypeptide of SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 144 or SEQ ID NO: 145. In certain embodiments, the methods of treatment or modulating the immune response include administering to the subject an engineered IL2 polypeptide of SEQ ID NO: 22, or of any one of SEQ ID NOs: 23-42. In certain embodiments, the methods of treatment or modulating the immune response include administering to the subject an engineered IL2 fusion polypeptide of SEQ ID NO: 51. In certain embodiments, the methods of treatment or modulating the immune

response include administering to the subject an engineered IL2 fusion polypeptide of SEQ ID NO: 43, or of any one of SEQ ID NOs: 44-63.

Suitable routes of administration include, but are not limited to, intravenous, parenteral, transdermal, oral, rectal, aerosol, ophthalmic, pulmonary, transmucosal, vaginal, otic, nasal, and topical administration. In addition, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.

In certain embodiments, an engineered IL2 polypeptide or IL2 fusion polypeptide is administered systemically. In certain embodiments, an engineered IL2 polypeptide or engineered IL2 fusion polypeptide as described herein is administered in a local rather than systemic manner, for example, via injection of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide directly into an organ, tissue, or tumor. In some embodiments, long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, in some embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ-specific or cell-specific antibody. In such embodiments, the liposomes are targeted to and taken up selectively by the organ. In some embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptide as described herein is provided in the form of a rapid release formulation, in the form of an extended or sustained release formulation, in the form of an intermediate release formulation, or in the form of a depot preparation. In some embodiments, the engineered IL2 polypeptide or engineered IL2 fusion polypeptide described herein is administered topically.

The appropriate dosage of an engineered IL2 polypeptide or engineered IL2 fusion polypeptide (used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease or condition, the route of administration, body weight of the subject, severity and progression of the disease, whether the polypeptide is administered for preventive or therapeutic purposes, previous or concurrent therapeutic interventions, the subject's clinical history and response to the engineered IL2 polypeptide or engineered IL2 fusion polypeptide, and the discretion of the attending physician. The practitioner responsible for administration

will be able to determine the concentration of active ingredient(s) in a composition and appropriate dosing for the subject to be treated. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.

5 A single administration of an engineered IL2 polypeptide may range from about 50,000 IU/kg to about 1,000,000 IU/kg or more of the engineered IL2 polypeptide. This may be repeated several times a day (*e.g.*, 2-4 times per day), for several days (*e.g.*, 3-5 consecutive days) and then may be repeated one or more times following a period of rest (*e.g.*, 7-14 days). Thus, a therapeutically effective amount
10 may comprise only a single administration or many administrations over a period of time (*e.g.* about 10-30 individual administrations of about 600,000 IU/kg of IL2 each given over about a 5-20 day period). When administered in the form of a fusion polypeptide, a therapeutically effective of the engineered IL2 fusion polypeptide may be lower than a non-fusion engineered IL2 polypeptide (*e.g.*, 10,000 IU/kg to about
15 600,000 IU/kg). Similarly, the engineered IL2 fusion polypeptide may be administered to the patient at one time or over a series of treatments as described above.

 In certain embodiments, the daily dosage of the engineered IL2 polypeptide or engineered IL2 fusion polypeptide ranges from about 1 µg/kg to about 100 mg/kg or more. For repeated administrations over several days or longer,
20 depending on the condition, the treatment may be sustained until a desired suppression of disease symptoms occurs (*e.g.*, tumor shrinkage). In some embodiments, a single dose of an engineered IL2 polypeptide or engineered IL2 fusion polypeptide is in the range from about 0.005 mg/kg to about 10 mg/kg. In some embodiments, a dose may be about 1 µg/kg/body weight, about 5 µg/kg/body weight, about 10 µg/kg/body weight,
25 about 50 µg/kg/body weight, about 100 µg/kg/body weight, about 200 µg/kg/body weight, about 350 µg/kg/body weight, about 500 µg/kg/body weight, about 1 mg/kg/body weight, about 5 mg/kg/body weight, about 10 mg/kg/body weight, about 50 mg/kg/body weight, about 100 mg/kg/body weight, about 200 mg/kg/body weight, about 350 mg/kg/body weight, about 500 mg/kg/body weight, to about 1000
30 mg/kg/body weight per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body

weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above. Such doses may be administered intermittently, *e.g.*, 2-3 times per day, every week, or every three weeks. An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful.

The engineered IL2 polypeptides and engineered IL2 fusion polypeptides described herein may be used in an amount effective to achieve the intended purpose. For use to treat or prevent a disease condition, the engineered IL2 polypeptides or engineered IL2 fusion polypeptides, or pharmaceutical compositions thereof, are administered in a therapeutically effective amount. Determination of a therapeutically effective amount is within the capabilities of those of skill in the art, especially in light of the details provided herein.

For systemic administration, a therapeutically effective amount can be estimated initially from in vitro assays, such as cell culture assays. A dose can then be formulated in animal models to achieve a circulating concentration range that includes the IC₅₀ as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Initial dosages can also be estimated from in vivo data, *e.g.*, animal models, using techniques that are well known in the art. Administration to humans could readily be optimized by a person of ordinary skill in the art based on animal data. Dosage amount and interval may each be adjusted to provide plasma levels of engineered IL2 polypeptides and engineered IL2 fusion polypeptides which are sufficient to maintain therapeutic effect. Levels in plasma may be measured, for example, by HPLC.

EXAMPLES

EXAMPLE 1

LIBRARY STRATEGY TO IDENTIFY IL2R α -REDUCED BINDING MUTATIONS

The libraries of IL2 mutations to identify IL2R α -reduced binders were rationally designed based on the structural modeling of IL2 interactions with IL2R α (Figs. 1A & 1B). Briefly, K35, R38, F42 and Y45 residues of IL2 were identified as the

important residues interacting with IL2R α (Fig. 1C). Mutagenic oligos carrying two, three and four randomized mutations at these residues were used for library construction (Table 1).

Table 1. Rationally designed IL2R α -reduced mutagenic libraries

		K35	R38	F42	Y45
Library 1	2 amino acid mutagenesis	NNS	NNS	F	Y
		NNS	R	NNS	Y
		NNS	R	F	NNS
		K	NNS	NNS	Y
		K	NNS	F	NNS
		K	R	NNS	NNS
Library 2	3 amino acid mutagenesis	NNS	NNS	NNS	Y
		NNS	R	NNS	NNS
		K	NNS	NNS	NNS
Library 3	4 amino acid mixed ratio mutagenesis	K50%/NNS50%	R50%/NNS50%	A50%/NNS50%	Y50%/NNS50%
		K70%/NNS30%	R70%/NNS30%	F70%/NNS30%	Y70%/NNS30%

5

Table 2. Mutagenic oligo design for IL-2R α -reduced binding libraries

Oligo #	Sequence	SEQ ID NO:
1	aac tac aag aac ccc NNS ctg acc NNS atg ctg acc ttc aag ttc tac atg cct aag aag gcc acc	171
2	aac tac aag aac ccc NNS ctg acc cgg atg ctg acc NNS aag ttc tac atg cct aag aag gcc acc	172
3	aac tac aag aac ccc NNS ctg acc cgg atg ctg acc ttc aag ttc NNS atg cct aag aag gcc acc	173
4	aac tac aag aac ccc aag ctg acc NNS atg ctg acc NNS aag ttc tac atg cct aag aag gcc acc	174
5	aac tac aag aac ccc aag ctg acc NNS atg ctg acc ttc aag ttc NNS atg cct aag aag gcc acc	175
6	aac tac aag aac ccc aag ctg acc cgg atg ctg acc NNS aag ttc NNS atg cct aag aag gcc acc	176
7	aac tac aag aac ccc NNS ctg acc NNS atg ctg acc NNS aag ttc tac atg cct aag aag gcc acc	177
8	aac tac aag aac ccc NNS ctg acc cgg atg ctg acc NNS aag ttc NNS atg cct aag aag gcc acc	178
9	aac tac aag aac ccc aag ctg acc NNS atg ctg acc NNS aag ttc NNS atg cct aag aag gcc acc	179
10	aac tac aag aac ccc AAG ctg acc CGG atg ctg acc GCC aag ttc TAC atg cct aag aag gcc acc	180
11	aac tac aag aac ccc AAG ctg acc CGG atg ctg acc GCC aag ttc TAC atg cct aag aag gcc acc	181

Upper case nucleotide trimer is mixed at 50% WT and 50% NNS, or 70% WT and 30% NNS, where “N” refers to any nucleotide, and “S” refers to G or C. Three libraries were composed by multi-step PCR and overlapping PCR of above mutagenic oligos with WT IL2 sequence as template. Library 1 includes mutagenic oligos 1-6, library 2 includes mutagenic oligos 7-9, and library 3 includes mutagenic oligos 10-11 (Table 2). Those mutagenic libraries have been further modified to have *in vitro* transcription and translation signal at the N-terminus. A flag-tag sequence was also added to the C-terminus for selection and purification purpose.

EXAMPLE 2

10 SELECTION AND IDENTIFICATION OF IL2R α -REDUCED BINDING CLONES

mRNA display technology was used to select IL2 mutants with IL2R α -reduced binding from the three IL2 mutagenic libraries. Briefly, the DNA libraries were first transcribed into mRNA libraries and then translated into mRNA-IL2 mutant fusion libraries by covalent coupling through a puromycin linker. The libraries were purified and converted to mRNA/cDNA fusion libraries. The fusion libraries were counter-selected with human and mouse IgGs (negative proteins) to remove nonspecific binders, then counter-selected against IL2R α three times. Library flow through (unbound molecules) was collected and PCR was performed to recover the IL2R α unbound molecules followed by gel purification. The recovered pool was subcloned into pET22b vector and expressed in E.coli Rosetta II strands. The supernatant of individual clones was tested in IL2R α binding ELISA. Fig. 2A shows the ELISA results of supernatant of selected IL2 clones to IL2R α . Fig. 2B shows the clone expression plotted against IL2R α binding with supernatant. Fig. 3 shows a sequence alignment of the clones identified with IL2R α -reduced binding.

25 EXAMPLE 3

BINDING KINETICS ANALYSIS OF IL2R α -REDUCED BINDING CLONES

The binding kinetics of IL2R α -reduced binding clones to IL2R α was assessed utilizing SPR technology with a Biacore T200, software version 2.0. For each

cycle, 1 ug/mL of human IL2R α was captured for 60 seconds at a flow rate of 10 uL/min on flow cell 2 in 1X HBSP buffer on a Protein A sensor chip. 100 nM of each HIS and Flag tag purified IL2 mutant was injected onto both the reference flow cell 1 and IL2R α captured flow cell 2 for 150 seconds at a flow rate of 30 uL/min followed by
5 washing for 300 seconds. The flow cells were then regenerated with Glycine pH 2.0 for 60 seconds at a flow rate of 30 uL/min. A HBSP+ buffer was included with each sample as a baseline control. The assay was set up in a 96-well format. The kinetics data was analyzed with Biacore T200 evaluation software 3.0. The specific binding response unit was derived from subtraction of binding to reference flow cell 1 from
10 IL2R α flow cell 2 and subtraction of buffer control. WT IL2 was included as control. Relative response (RU) was determined for each IL2R α -reduced binding clone (Fig. 4, Table 3).

Table 3. Binding kinetics analysis of IL2R α -reduced binding clones

Clone	Cycle Number	RU (at 100 nM)	Relevant binding to WT IL2 (%)
Buffer	3	-0.1	0
WT IL2	44	142	100
EP001	50	2.2	1.55
EP003	52	40.8	28.73
EP101	4	2.5	1.76
EP120	6	3.6	2.54
EP121	8	3.4	2.39
EP125	10	6.1	4.29
EP119	12	2.7	1.9
EP115	14	2.4	1.69
EP126	16	2.6	1.83
EP117	18	2.5	1.76
EP122	20	2.5	1.76
EP108	22	2.4	1.69
EP100	24	1.7	1.19
EP110	26	2.6	1.83
EP105	28	2.1	1.48
EP113	30	2.6	1.83
EP123	32	5.3	3.73
EP111	34	2.8	1.97
EP104	36	2.8	1.97
EP103	38	2.9	2.04
EP112	40	2.9	2.04
EP102	42	2.7	1.9
EP225	46	7.4	5.21
EP226	48	3	2.11

EXAMPLE 4

LIBRARY STRATEGY TO GENERATE IL2R β AGONISTS

Engineered IL2R β binding agonists were created by rational IL2 mutagenic library design followed by selection with mRNA display technology platform. Briefly, two WT IL2 binding regions to IL2R β were identified: IL2R β binding region 1 “QLQLEHLLLDLQM” (SEQ ID NO: 67) and IL2R β binding region 2 “RPRDLISNINVIVLE” (SEQ ID NO: 68) from structural analysis. For production of mutagenic libraries including mutations to IL2R β binding region 1, IL2R β binding region 2, or IL2R β binding region 1 and IL2R β binding region 2, two mutagenic oligomers (Oligo 1, Oligo 2) encoding the sequences of these two regions were designed (Table 4). For Oligo 1 and Oligo 2 sequences, each codon trimer with nucleotides shown as lower-case letters was a mixture of 50% WT and 50% NNS (with “N” referring to any nucleotide, and “S” referring to G or C). Additional oligomers (Oligo 3 to Oligo 12) coding WT IL2 sequences were designed from WT region for mutagenic library assembly (Table 4). Three mutagenic libraries were constructed using these oligos (Fig. 5). Library 4 was constructed using an overlapped PCR strategy with mutagenic oligo 1 and oligos 3-12. Library 5 was constructed using an overlapped PCR strategy with mutagenic oligo 2 and oligos 3-9, 11, and 12. Library 6 was constructed using an overlapped PCR strategy with mutagenic oligos 1 and 2 and oligos 3-8, 11, and 12. The three mutagenic libraries were further modified to have an *in vitro* transcription and translation signal at N-terminus and a Flag-tag at the C-terminus for selection with mRNA display.

Table 4. Mutagenic oligo design for IL-2R β agonist libraries

Oligo #	Sequence	SEQ ID NO:
1	AGT TCT ACA AAG AAA ACA cag cta caa ctg gag cat tta ctg ctg gat tta cag atg ATT TTG AAT GGA ATT AAT	69
2	AGC AAA AAC TTT CAC TTA aga ccc agg gac tta atc agc aat atc aac gta ata gtt ctg gaa CTA AAG GGA TCT GAA ACA	70
3	AATTACTATTTACAATTACAATGGCTAGCGCACCTACTTC AAGTTCTACAAAGAAAACA	71

Oligo #	Sequence	SEQ ID NO:
4	CTTGGGCATGTAAAACTTAAATGTGAGCATCCTGGTGAG TTTGGGATTCTTGTAATTATTAATTCCATTCAAAT	72
5	AAGTTTTACATGCCCAAGAAGGCCACAGAACTGAAACAT CTTCAGTGTCTAGAAGAAGAAGAACTCAAACCTC	73
6	TAAGTGAAAGTTTTTGTCTTTGAGCTAAATTTAGCACTTCC TCCAGAGGTTTGA GTTCTTC	74
7	CTAAAGGGATCTGAAACAACATTCATGTGTGAATATGCT GATGAGACAGCAACCAATTGTAGAATTTCTGAACAGA	75
8	AGATGGTGCAGCCACAGTTCGAGTCAGTGTTGAGATGAT GCTTTGACAAAAGGTAATCCATCTGTTCAGAAATTCTAC	76
9	AGTTCTACAAAGAAAACACAGCTACAACCTGGAGCATTTA CTGCTGGATTTACAGATGATTTTGAATGGAATTAAT	77
10	AGCAAAAACCTTTCACTTAAGACCCAGGGACTTAATCAG CAATATCAACGTAATAGTTCTGGAACATAAGGGATCTGAAACA	78
11	AAGTTTTACATGCCCAAG	79
12	TAAGTGAAAGTTTTTGC	80

EXAMPLE 5

SELECTION AND IDENTIFICATION OF IL2R β AGONIST CLONES

An mRNA display technology platform was used for the identification of IL2R β agonists from three IL2 mutagenic libraries. The DNA libraries were first transcribed into mRNA libraries and then translated into mRNA-IL2 mutant fusion libraries by covalent coupling through a puromycin linker. The libraries were then purified and converted to mRNA/cDNA fusion libraries (*see, e.g.*, US Patent No. 6,258,558, hereby incorporated by reference). The fusion libraries were first counter selected with human IgGs (negative proteins) to remove nonspecific binders, then counter selected to remove IL2R α binders, followed by selection against recombinant IL2R β /Fc protein captured on Protein G magnetic beads. The IL2R β binders were recovered and enriched by PCR amplification. A total of five rounds of selections were executed to generate highly enriched engineered IL2 mutants binding to IL2R β .

Following five rounds of selection, enriched libraries were cloned into bacterial periplasmic expression vector pET22b and transformed into TOP10 competent

E. coli cells. Each engineered IL2 molecule was engineered to have a C-terminus flag and 6xHIS tag for purification and assay detection. Clones from TOP10 cells were pooled and the miniprep DNA were prepared and subsequently transformed into *E. coli* Rosetta II strain for expression. Single clones were picked, grown and induced with
5 0.25 mM IPTG in 96-well plates for expression. The supernatant was collected after 16 to 24 hours induction at 30°C for assays to identify binders.

Supernatants containing engineered IL2 mutants were assessed with sandwich ELISA assay to screen for expression. Briefly, an anti-HIS tag antibody (R&D Systems) was immobilized in a 96-well plate at a final concentration of 2 µg/mL
10 in 1X PBS in a total volume of 50 µL per well. The plate was incubated overnight at 4°C followed by blocking with 200 µL of superbloc per well for 1 hour. 100 µL of 1:10 1X PBST diluted supernatant was added to each well and incubated for 1 hour with shaking. The expression level of engineered IL2 mutant was detected by adding 50 µL of anti-Flag HRP diluted at 1:5000 in 1X PBST for one hour. In between each step,
15 the plate was washed three times with 1X PBST using a plate washer. The plate was then developed with 50 µL of TMB substrate for 5 minutes and stopped by adding 50 µL of 2N sulfuric acid. The plate was read at OD₄₅₀ nm using a Biotek plate reader and the data was analyzed with Prism 8.1 software.

Single clones were next screened for IL2Rβ binding. IL2Rβ binding
20 screening ELISA was developed for the identification of individual engineered IL2 mutant. Briefly, 96-well plate was immobilized with human Fc and human IL2Rβ, respectively, at a final concentration of 2 µg/mL in 1X PBS in total volume of 50 µL per well. The plate was incubated overnight at 4°C followed by blocking with 200 µL of superbloc per well for 1 hour. 100 µL of supernatant was added to both Fc and
25 IL2Rβ immobilized wells and incubated for 1 hour with shaking. The engineered IL2 mutant binding was detected by adding 50 µL of anti-Flag HRP diluted at 1:5000 in 1X PBST. In between each step, the plate was washed three times with 1X PBST in a plate washer. The plate was then developed with 50 µL of TMB substrate for five minutes and stopped by adding 50 µL of 2N sulfuric acid. The plate was read at OD₄₅₀ nm

using a Biotek plate reader and the binding and selectivity was analyzed. The correlation of expression and IL2R β binding was plotted with Prism 8.1 software.

High IL2R β -binding clones (shown to the right of the vertical OD450 nm cutoff) were identified from library 5 for further characterization as engineered IL2R β agonists (Fig. 6). The IL2R β -binding activity of the clones generally correlated with expression level of the clones. Multiple sequence alignment of the IL2R β binding region 2 revealed both highly conserved and highly varied amino acids as compared to IL2 WT, as well as clone sequences that were identified multiple times independently (Fig. 7). No specific IL2R β -binding clones were identified from libraries 4 and 6.

10

EXAMPLE 6

PRODUCTION OF IL2R β AGONIST CLONES IN *E. COLI* AND MAMMALIAN CELLS

For production of the IL2R β agonists in *E. coli*, the glycerol stock of each engineered agonist clone was inoculated into TB medium for overnight growth. The next day, cells from the overnight culture were inoculated into TB medium and grown to a cell density of OD₆₀₀ between 0.6-0.8. IPTG was added to a final concentration of 1 mM to induce the expression during culture at 30 degrees C overnight. The supernatant was collected by centrifugation. The engineered agonists were purified by Ni-Sepharose (GE Healthcare) affinity column according to the manufacturer's protocol. The purity of the engineered agonists was further improved by Flag-tag affinity column purification (Sigma). The agonists were each concentrated and loaded to a Sephadex 200 Increase 10/300 GL column in AKTA for size exclusion chromatographic column purification. The high homogeneous monomeric peak fractions of the agonists were each pooled and concentrated. Endotoxin was further removed using endotoxin removal resin (Pierce) according to the standard protocol. The final endotoxin level was less than 10 EU/mg. Protein purity was confirmed by LC-MS spectrometry analysis and SDS gel (Fig. 8). The proteins were each stored in 1X PBS buffer for binding and functional analysis.

For production of the IL2R β agonists in mammalian cells, the DNA sequence corresponding to the amino-acid sequence was codon optimized, synthesized

and subcloned into pCDNA3.4 (Invitrogen). Each engineered IL2 polypeptide was expressed transiently in ExpiHEK293-F cells in free style system (Invitrogen) according to standard protocol. The cells were grown in the above conditions for seven days before harvesting. The supernatant was collected by centrifugation and filtered
5 through a 0.2 μ m PES membrane. The agonists were first purified by Ni Sepharose Excel resin column (GE Healthcare) and buffer exchanged to PBS pH 7.4 + 300mM NaCl (total) with 7k Da Zeba columns. Each polypeptide was then concentrated to 1 mL and purified by a Superdex 200 Increase 10/300 GL column (GE Healthcare) to homogeneity. The monomeric peak fractions were pooled and concentrated. The final
10 purified protein contained less 10 EU/mg endotoxin. The IL2 polypeptide identify was confirmed by LC-MS spectrometry analysis and purity analyzed by SDS gel. The proteins were stored in 1X PBS/300 nM NaCl buffer for binding, functional and mechanism analysis.

EXAMPLE 7

15 BINDING KINETICS ANALYSIS OF IL2R β AGONIST CLONES USING SURFACE PLASMON RESONANCE

The binding kinetics of *E. coli* produced WT IL2 and EP001-EP007 were assessed by surface plasmon resonance technology with Biacore T200 for engineered IL2 polypeptides produced in *E. coli* cells and engineered IL2 polypeptides
20 produced in mammalian cells. The assay was run with Biacore T200 control software version 2.0. For each cycle, 1 μ g/mL of human IL2R β or IL2R α was captured for 60 seconds at flow rate of 10 μ L/min on flow cell 2 in 1X HBST buffer on Protein A sensor chip. Two-fold serial diluted HIS tag purified engineered IL2 mutant was injected onto both reference flow cell 1 and IL2R β or IL2R α captured flow cell 2 for
25 150 seconds at flow rate of 30 μ L/min followed by washing for 300 seconds. The flow cells were then regenerated with Glycine pH 2 for 40 seconds at a flow rate of 30 μ L/min. Eight concentration points from 0 to 100 nM were assayed for each IL2R β agonist clone 96-well plate format. The kinetics data was analyzed with Biacore T200

evaluation software 3000. The specific binding response unit was derived from subtraction of binding to reference flow cell 1 from target flow cell 2.

WT IL2 was used to validate the binding protocols and was included in each run as a control (Figs. 9A & 9B). Representative sensorgrams of binding kinetics of *E. coli* and mammalian produced IL2R β agonist binding to IL2R α (Figs. 10A-10H for *E. coli* produced, Figs. 12A-12D for mammalian produced) and IL2R β (Figs. 11A-11H for *E. coli* produced, Figs. 13A-13D for mammalian produced) are shown. Binding kinetics for *E. coli*-produced IL2 (Table 5) and mammalian-produced IL2 (Table 6) are summarized.

IL2R β agonists EP001, EP006, and EP007 demonstrated no detectable IL2R α binding or a significant decrease (greater than a twenty-fold decrease) in IL2R α binding, but had a significant increase in IL2R β binding as compared to WT IL2 (Table 5, 6). In contrast, the IL2R β agonists EP002, EP003, EP004, and EP005 did not demonstrate a significant decrease in IL2R α (less than a twenty-fold decrease) as compared to wild-type IL2, but had a significant increase in IL2R β binding as compared to WT IL2 (Tables 5, 6).

Table 5. Summary of IL2R binding kinetics of *E. coli*-produced IL2R β agonist clones

Clones	IL2 α	IL2R β			Relative activity	
	KD* (M)	Kon (1/Ms)	Koff (1/s)	KD (M)	IL2R α (KD: fold)	IL2R β (KD: fold)
WT IL2	9.51E-09	5.83E+04	0.253	4.34E-06	-	-
EP001	ND	3.26E+06	0.003646	1.12E-09	NA	3888
EP002	1.01E-07	1.15E+06	0.002734	2.37E-09	-10.6	1834
EP003	2.14E-08	2.18E+06	2.70E-04	1.23E-10	-2.3	35194
EP004	4.05E-08	3.05E+06	0.001892	6.20E-10	-4.3	7007
EP005	1.26E-08	6.10E+06	0.005397	8.85E-10	-1.3	4909
EP006	4.81E-07	8.19E+05	0.002541	3.10E-09	-50.6	1399
EP007	ND	7.09E+05	2.63E-04	3.70E-10	NA	11728

Table 6. Summary of IL2R binding kinetics of mammalian-produced IL2R β agonist clones

Clones	IL2 α	IL2R β			Relative activity	
	KD* (M)	Kon (1/Ms)	Koff (1/s)	KD (M)	IL2R α (KD: fold)	IL2R β (KD: fold)
WT IL2	1.35E-08	3.26E+03	0.00329	1.01E-06	-	-
EP001	ND	5.61E+06	0.00417	7.43E-10	NA	1359
EP003	3.02E-07	2.59E+06	0.000376	1.45E-10	-22.4	6966
EP004	2.88E-08	5.18E+06	2.15E-03	4.14E-10	-2.1	2422

EXAMPLE 8

IL2R β AGONIST P-STAT5 ACTIVATION IN HUMAN PBMCs

- Human PBMCs were isolated from peripheral blood of three separate donors and plated at 250,000 cells/well in a 96-well plate in 75 μ L of media. Cells were rested 1 hr at 37°C. Cells were stimulated with human WT IL2 and engineered His-Flag tagged IL2 at 4X concentration in 25 μ L for 20 min at 37°C. Stimulated PBMCs were immediately fixed, permeabilized, stained for cell lineage markers (CD3, CD56, CD4, CD8, FOXP3) and p-STAT5 and visualized on the Attune flow cytometer. CD8+ T cells were defined as CD3+CD56-CD4-CD8+. NK cells were defined as CD3-CD56+. T regulatory cells were defined as CD3+CD56-CD4+CD8-FOXP3+. The % of cells that were p-STAT5+ was determined and graphed versus each IL2 titration (Figs. 14A-14C for blood donor 1, Figs. 14D-14F for blood donor 2, and Figs. 14G-14I for blood donor 3). EC50 values for P-STAT5 activation were determined using Prism software (Table 7).

Table 7. Summary of P-STAT5 activation of human CD8+ T cells, NK cells and Tregs

		EC50 (nM)			
		WT	EP001	EP003	EP004
Blood Donor 1	CD8+ T Cells	8.9E-01	1.9E-02	1.1E-02	2.1E-02
	NK Cells	1.5E-01	1.4E-03	3.1E-04	1.4E-03
	T Regulatory Cells	9.5E-05	2.2E-03	<1.0E-5	<1.0E-5
	CD8+ T Cells	5.6E-01	1.6E-02	1.7E-02	7.1E-03

		EC50 (nM)			
		WT	EP001	EP003	EP004
Blood Donor 2	NK Cells	1.5E-01	1.1E-03	4.2E-04	7.1E-04
	T Regulatory Cells	4.2E-05	1.4E-03	<1.0E-5	<1.0E-5
Blood Donor 3	CD8+ T Cells	1.1E+00	2.3E-02	2.6E-02	1.2E-02
	NK Cells	2.6E-01	3.3E-03	1.4E-03	1.8E-03
	T Regulatory Cells	2.0E-05	3.2E-03	<1.0E-5	<1.0E-5

EXAMPLE 9

RATIONAL GENERATION OF IL2R β AGONIST BACK-MUTATION CLONES

Rationally designed IL2R β agonist back-mutation strategy was carried out to create a range of IL2R β agonist candidate mutations. EP001 contains R81T, P82A, L85A, I86V, S87D, I89M, N90R, V93I and L94Q mutations. Four back mutations to WT IL2 were designed for each candidate. The I86 and I89 were back-mutated to 86I and 89I of WT IL2 for all mutations. A systemic back-mutation was then applied to the other two residues in combination with 86I and 89I. A total of 21 back-mutation combinations were designed and the mutations were created by site directed mutagenesis using EP001 as template (Table 8). IL2R β agonist back-mutation clones were sequence verified after mutagenesis.

Table 8. Back mutations introduced into EP0001

	81	82	85	86	87	89	90	93	94
WT IL2	R	P	L	I	S	I	N	V	L
EP001	T	A	A	V	D	M	R	I	Q
EP242	T	A	A	I	S	I	R	V	Q
EP243	R	P	A	I	D	I	R	I	Q
EP244	R	A	L	I	D	I	R	I	Q
EP245	R	A	A	I	S	I	R	I	Q
EP246	R	A	A	I	D	I	N	I	Q
EP247	R	A	A	I	D	I	R	V	Q
EP248	R	A	A	I	D	I	R	I	L
EP249	T	P	L	I	D	I	R	I	Q
EP250	T	P	A	I	S	I	R	I	Q
EP251	T	P	A	I	D	I	N	I	Q
EP252	T	P	A	I	D	I	R	V	Q

	81	82	85	86	87	89	90	93	94
EP253	T	P	A	I	D	I	R	I	L
EP254	T	A	L	I	S	I	R	I	Q
EP255	T	A	L	I	D	I	N	I	Q
EP256	T	A	L	I	D	I	R	V	Q
EP257	T	A	L	I	D	I	R	I	L
EP258	T	A	A	I	S	I	N	I	Q
EP260	T	A	A	I	S	I	R	I	L
EP261	T	A	A	I	D	I	N	V	Q
EP262	T	A	A	I	D	I	N	I	L
EP263	T	A	A	I	D	I	R	V	L

EXAMPLE 10

CHARACTERIZATION OF IL2R β AGONIST-BACK-MUTATION CLONES

EP001 back-mutation clones were characterized for their binding activities to IL2R β and IL2R α receptors by ELISA. Briefly, 384 well plate was immobilized with human IL2R α and IL2R β Fc fusion proteins at a final concentration of 2 ug/mL in 1X PBS in total volume of 25 uL per well. The plate was incubated overnight at 4C and blocked with 80 uL of superbloc per well for 1 hour. The purified EP001 back-mutation clones were serially diluted from 100 nM to 0 nM. Each dilution was added to IL2R α or IL2R β wells in parallel in duplicates. The IL2 mutant binding was detected by adding 25 uL of anti-Flag HRP diluted at 1:5000 in 1X PBST. In between each step, the plate was washed three times with 1X PBST using a plate washer. The plate was then developed with 25 uL of TMB substrate for five minutes and stopped by adding 25 ul of 2N sulfuric acid. The plate was read at OD450 nm by Biotek plate reader and the EC50 was analyzed with Prism 8.1 software to generate EC50 values (Fig. 15A for IL2R α , and Fig. 15B for IL2R β , summarized in Table 9).

Table 9. Binding activity of back-mutation clones

Clone	IL2R α Binding	IL2R β Binding
	EC50 (nM)	EC50 (nM)
WT IL2	1.2	ND
EP001	259.0	0.7
EP003	538.5	1.8
EP242	8.7	5.7
EP243	6.7	217.1
EP244	10.2	2830.0
EP245	4.8	122.8
EP246	7.0	269.0
EP247	8.3	4.7
EP248	13.4	188.0
EP249	20.2	576.1
EP250	13.2	23.4
EP251	16.8	2.5
EP252	13.0	2.2
EP253	48.5	4.8
EP254	4.3	556.1
EP255	4.3	359.5
EP256	5.3	361.9
EP257	5.6	ND
EP258	2.5	6.5
EP260	5.4	1.1
EP261	2.9	124.5
EP262	32.1	53.2
EP263	4.9	1.3

EXAMPLE 11

BINDING KINETICS OF IL2R β AGONIST BACK-MUTATION CLONES USING SURFACE
PLASMON RESONANCE

5 Binding kinetics analysis of EP001 back-mutation clones have been assessed by SPR technology with a Biacore T200. The assay was run with Biacore T200 control software version 2.0. For each cycle, 1 ug/mL of human IL2R β was captured for 60 seconds at flow rate of 10 uL/min on flow cell 2 in 1X HBSP buffer on Protein A sensor chip. 100 nM of HIS and Flag tag purified each IL2 mutant was 2-fold
10 serial diluted and injected onto both reference flow cell 1 and IL2R β captured flow cell 2 for 150 seconds at flow rate of 30 uL/min followed by washing for 300 seconds. The

flow cells were then regenerated with Glycine pH2 for 60 seconds at a flow rate of 30 uL/min. The assay was set up with 8 serial diluted concentration points in 96-well format. The kinetics data was analyzed with Biacore T200 evaluation software 3.0. The specific binding response unit was derived from subtraction of binding to reference
 5 flow cell 1 from target flow cell 2 (Figs. 16A-16F, Table 10).

Table 10. Summary of binding kinetics for back-mutation clones. (NA: data not available; *: KD measured from steady state affinity fitting)

	ka (1/Ms)	kd (1/s)	KD (M)
EP001	3.86E+06	5.89E-03	1.52E-09
EP242	3.36E+06	2.41E-02	7.16E-09
EP247	4.20E+06	3.04E-02	7.23E-09
EP252	NA	NA	9.110E-9*
EP253	NA	NA	2.947E-8*
EP258	3.42E+06	3.01E-02	8.81E-09
EP260	1.06E+07	2.24E-02	2.11E-09
EP263	6.84E+06	1.91E-02	2.79E-09

EXAMPLE 12

ENGINEERED IL2R β AGONISTS WITH REDUCED IL2R α ACTIVITY

10 IL2 mutations with potentially reduced or eliminated IL2R α binding generated through mRNA library selection and screen were first expressed in *E.coli* and purified by Ni-Sepharose (GE Healthcare) affinity column and Flag tag affinity column purification (Sigma) according to the manufacturer's protocol. The IL2 mutations with significant reduced IL2R α binding activities confirmed by both Biacore SPR binding
 15 and ELISA binding were then selected for generating IL2R β agonists with reduced IL2R α binding activities. Briefly, mutations were introduced by site directed mutagenesis technologies to IL2R β agonist constructs in pCDNA3.4 mammalian expression vector and confirmed by DNA sequence analysis (Table 11). Each engineered IL2 polypeptide was expressed transiently in ExpiHEK293-F cells in free
 20 style system (Invitrogen) according to standard protocol. The cells were grown in above conditions for five days before harvesting. The supernatant was collected by

centrifugation and filtered through a 0.2 μ m PES membrane. The agonists were first purified by Ni Sepharose Excel resin column (GE Healthcare) and further purified by a Superdex 200 Increase 10/300 GL column (GE Healthcare) to more than 95% homogeneity (Fig. 17). The final purified proteins have less than 10 EU/mg endotoxin.

- 5 The proteins were stored in 1X PBS buffer for binding, functional and mechanism analysis.

Table 11. Engineered IL2R β agonists with IL2R α reduced-binding mutations

Engineered IL2R β agonist with IL2R α Reduced Activity	Parental IL2R α -Reduced Binding Clones	IL2R α Mutations	Parental IL2R β Agonist Clone
EP329	EP103	K35G/R38E	EP260
EP330		K35G/R38E	EP258
EP331		K35G/R38E	EP252
EP332		K35G/R38E	EP253
EP333	EP104	K35S,F42G	EP260
EP334		K35S,F42G	EP258
EP335		K35S,F42G	EP252
EP336		K35S,F42G	EP253
EP337	EP110	K35L/R38D/F42R	EP260
EP338		K35L/R38D/F42R	EP258
EP339		K35L/R38D/F42R	EP252
EP340		K35L/R38D/F42R	EP253
EP341	EP112	R38D/Y45S	EP260
EP342		R38D/Y45S	EP258
EP343		R38D/Y45S	EP252
EP344		R38D/Y45S	EP253
EP345	EP121	R38V/Y45S	EP260
EP346		R38V/Y45S	EP258
EP347		R38V/Y45S	EP252
EP348		R38V/Y45S	EP253
EP349	EP239	F42A	EP260
EP350		F42A	EP258
EP351		F42A	EP252
EP352		F42A	EP253

EXAMPLE 13

BINDING KINETICS ANALYSIS OF ENGINEERED IL2R α /IL2R β CLONES USING SURFACE
PLASMON RESONANCE

Kinetic analysis of the receptor binding activities of IL2R β agonist with
 5 IL2R α reduced activity mutations have been assessed by SPR technology with Biacore
 T200. The assay was run with Biacore T200 control software version 2.0. For each
 cycle, 1 ug/mL of human IL2R β was captured for 60 seconds at flow rate of 10 ul/min
 on flow cell 2 in 1XHBSP buffer on Protein A sensor chip. 100 nM of HIS and Flag tag
 purified each IL2 mutant was 2 fold serial diluted and injected onto both reference flow
 10 cell 1 and IL2R β captured flow cell 2 for 150 seconds at flow rate of 30 ul/min
 followed by wash for 300 seconds. The flow cells were then regenerated with Glycine
 pH2 for 60 seconds at flow rate of 30 ul/min. The assay was set up with 8 serial diluted
 concentration points in 96 well format. The kinetics data was analyzed with Biacore
 T200 evaluation software 3.0. The specific binding response unit was derived from
 15 subtraction of binding to reference flow cell 1 from target flow cell 2. Figs. 18A-18H
 show titrated binding of engineered IL2R β / α clones to IL2R α , and Figs. 19A-19H show
 titrated binding of engineered IL2R β / α clones to IL2R β . A description of the clones as
 well as a summary of the kinetics data are shown in Table 12.

Table 12. Summary of binding kinetics of engineered IL2R β /IL2R α clones to human

20

IL2R α

			IL2R α	IL2R β		
Clone	IL2R α Binding Mutations	IL2R β Binding Mutations	Binding	ka (1/Ms)	kd (1/s)	KD (M)
EP397	K35G/R38E	WT	NA	NA	NA	NA
EP398	K35G/R38E	EP001	NA	NA	NA	NA
EP399	K35G/R38E	EP003	NA	NA	NA	NA
EP400	K35S/F42G	WT	NA	NA	NA	NA

			IL2R α	IL2R β		
Clone	IL2R α Binding Mutations	IL2R β Binding Mutations	Binding	ka (1/Ms)	kd (1/s)	KD (M)
EP401	K35S/F42G	EP001	ND	7.21E+06	0.006164	8.55E-10
EP402	K35S/F42G	EP003	ND	3.68E+06	3.97E-04	1.08E-10
EP403	K35L/R38D/F42R	WT	NA	NA	NA	NA
EP404	K35L/R38D/F42R	EP001	NA	NA	NA	NA
EP405	K35L/R38D/F42R	EP003	NA	NA	NA	NA
EP406	R38D/Y45S	WT	ND	NA	NA	NA
EP407	R38D/Y45S	EP001	ND	8.34E+06	0.005094	6.11E-10
EP408	R38D/Y45S	EP003	ND	2.56E+06	5.98E-04	2.33E-10
EP409	R38V/Y45S	WT	Low	1.49E+05	0.005308	3.57E-08
EP410	R38V/Y45S	EP001	Low	7.19E+06	0.00594	8.27E-10
EP411	R38V/Y45S	EP003	Low	1.82E+06	8.39E-04	4.61E-10

NA: data not available. ND: Non-detectable binding. Low: Binding signal below 10 RU.

Figs. 20A-20G show IL2R α single concentration binding, and Figs. 21A-21G show IL2R β single concentration binding, and Figs. 22A and 22B show IL2R α multi-concentration binding, which are summarized in Table 13).

Table 13. Summary of binding kinetics of engineered IL2R β /IL2R α clones to human IL2R by SPR

	Single-Concentration KD (M)							Multi-Concentration KD (M)			
	WT IL2	EP329	EP333	EP337	EP341	EP345	EP349	EP337	EP338	EP339	EP340
IL2R α	1.05E-08	Very low	Very low	ND	ND	Low	Low	ND	ND	ND	ND
IL2R β	NA#	1.22E-09	1.41E-09	3.80E-09	2.54E-09	1.25E-08	2.79E-09	1.44E-08	3.83E-08	3.59E-08	NA#

ND: Non-detectable binding. Low: Binding signal below 5 RU

EXAMPLE 14

ELISA BINDING ANALYSIS OF ENGINEERED IL2R α /IL2R β CLONES

- Recombinant Fc-tagged human IL2R α and IL2R β were added in 25 μ L of 1X PBS to wells of 384-well plate and incubated overnight at 4 °C to coat the plates.
- 5 Plates were washed three times with 0.05% Tween20/1X PBS. Plates were blocked with 100 μ L of SuperBlock for 1 hr at RT and then washed 3 times with 0.05% Tween20/1X PBS. IL2 mutants were diluted in 0.05% Tween 20/1X PBS from 1000 nM to 0 nM and added to plates for 2 hrs at room temperature. Plates were then washed 6 times with 0.05% Tween20/1X PBS. Anti-HisTag-HRP was diluted 1:5000 in 0.05% Tween20/1X PBS and added to plates for 1 hr at RT. Plates were then washed 6 times with 0.05% Tween 20/1X PBS, and TMB was added to develop blue color. Reactions were stopped with 2N hydrogen sulfide and light absorbance at 450 nm was read on a BioTek plate reader. Single point absorbance for human IL2R α and titrations for human IL2R α and IL2R β are graphed (Figs. 23A-23E for IL2R α , Figs. 24A-24D for IL2R β). A
- 15 summary of the EC50 values of ELISA binding is shown (Table 14).

Table 14. Summary of ELISA binding to human IL2R α and IL2R β

	EC50 (nM)								
	WT IL2	EP001	EP252	EP331	EP335	EP339	EP343	EP347	EP351
IL2R α	11.5	ND	13.81	ND	ND	ND	ND	ND	ND
IL2R β	ND	8.1	24.5	39.3	59.1	96.3	19.7	77.6	21.2
			EP253	EP332	EP336	EP340	EP344	EP348	EP352
IL2R α			8.9	ND	ND	ND	ND	ND	ND
IL2R β			52.8	44.0	133.0	185.0	50.7	123.7	33.8
			EP258	EP330	EP334	EP338	EP342	EP346	EP350
IL2R α			9.1	ND	ND	ND	ND	ND	ND
IL2R β			119.2	ND	28.6	105.3	58.9	ND	39.9

	EC50 (nM)								
	WT IL2	EP001	EP252	EP331	EP335	EP339	EP343	EP347	EP351
			EP260	EP329	EP333	EP337	EP341	EP345	EP349
IL2R α			12.9	ND	ND	ND	ND	ND	ND
IL2R β			295.9	11.4	11.4	137.9	64.1	152.1	947.8

EXAMPLE 15

P-STAT5 ACTIVATION OF HUMAN PBMCs BY ENGINEERED IL2R α /IL2R β CLONES

Human PBMCs were isolated from peripheral blood of two donors and plated at 250,000 cells/well in a 96-well plate in 75 μ L of media. Cells were rested 1 hr at 37°C. Cells were stimulated with human IL2 WT and engineered His-Flag tagged IL2 at 4X concentration in 25 μ L for 20 min at 37°C. Stimulated PBMCs were immediately fixed, permeabilized, stained for cell lineage markers (CD3, CD56, CD4, CD8, FOXP3) and p-STAT5 and visualized on the Attune flow cytometer. CD8⁺ T cells were defined as CD3⁺CD56⁻CD4⁻CD8⁺. NK cells were defined as CD3⁻CD56⁺. T regulatory cells were defined as CD3⁺CD56⁻CD4⁺CD8⁻FOXP3⁺. The % of cells that were p-STAT5⁺ was determined and graphed versus each IL2 titration (Figs. 25A-25D for donor 656 CD8⁺ T cells, Figs. 26A-26D for donor 648 CD8⁺ T cells, Figs. 27A-27D for donor 656 NK cells, Figs. 28A-28D for donor 648 NK cells, Figs. 29A-29D for donor 656 T regulatory cells, and Figs. 30A-30D for donor 648 T regulatory cells). A summary of the EC50 values of P-STAT5 activation in each cell type is shown in Table 15 for blood donor 1 and Table 16 for blood donor 2.

Table 15. Summary of P-STAT5 activation of human CD8⁺ T cells, NK cells and Tregs
for donor 1.

	EC50 (nM)								
	Blood Donor 1								
	WT	EP001	EP252	EP331	EP335	EP339	EP343	EP347	EP351
CD8 ⁺ T Cells	6.1E-01	4.7E-02	2.4E-02	5.6E-01	3.6E-01	1.2E-01	1.9E-01	9.4E-02	9.7E-02
NK Cells	2.8E-01	1.0E-02	1.1E-02	1.3E-01	8.2E-02	3.8E-02	1.3E-02	1.2E-02	9.9E-03
T Regulatory Cells	2.0E-03	1.8E-02	2.5E-05	2.9E-01	6.1E-02	1.0E-01	4.3E-02	7.6E-03	1.1E-02
	WT	EP001	EP253	EP332	EP336	EP340	EP344	EP348	EP352
CD8 ⁺ T Cells	6.1E-01	4.7E-02	4.5E-02	8.1E-01	1.0E-01	3.1E-01	4.0E-01	4.8E-01	1.4E-01
NK Cells	2.8E-01	1.0E-02	1.1E-02	3.2E-01	1.5E-02	1.0E-01	5.5E-02	1.2E-01	1.3E-02
T Regulatory Cells	2.0E-03	1.8E-02	3.7E-04	3.2E-01	1.3E-02	1.3E-01	9.1E-02	3.9E-02	1.2E-02
	WT	EP001	EP258	EP330	EP334	EP338	EP342	EP346	EP350
CD8 ⁺ T Cells	2.7E-01	8.6E-02	2.2E-02	8.0E+00	4.7E-01	3.3E-01	4.0E-01	1.3E-01	2.0E-01
NK Cells	8.7E-01	1.7E-02	1.3E-02	ND	ND	3.8E-02	5.7E-02	3.4E-02	1.8E-02
T Regulatory Cells	2.4E-04	1.9E-02	<1E-4	2.8E-01	2.7E-02	9.6E-02	9.1E-02	N.D.	2.1E-02
	WT	EP001	EP260	EP329	EP333	EP337	EP341	EP345	EP349
CD8 ⁺ T Cells	2.7E-01	8.6E-02	1.7E-02	1.6E-01	2.5E-01	6.3E-02	1.0E-01	5.2E-01	8.4E-02
NK Cells	8.7E-01	1.7E-02	1.5E-01	1.4E-01	5.0E-02	ND	1.2E-02	8.1E-02	2.8E-02
T Regulatory Cells	2.4E-04	1.9E-02	<1E-4	2.8E-01	2.7E-02	9.6E-02	9.1E-02	ND	2.1E-02

Table 16. Summary of P-STAT5 activation of human CD8⁺ T cells, NK cells and Tregs
for donor 2.

	EC50 (nM)								
	Blood Donor 2								
	WT	EP001	EP252	EP331	EP335	EP339	EP343	EP347	EP351
CD8 ⁺ T Cells	9.9E+00	6.8E-02	3.5E-01	5.7E-01	2.6E-01	3.0E-01	1.5E-01	1.7E-01	1.1E-01
NK Cells	1.3E+00	1.0E-02	1.2E-02	7.6E-02	2.1E-02	5.0E-02	1.1E-02	2.1E-02	1.8E-02
T Regulatory Cells	3.8E-03	1.3E-02	2.5E-06	7.0E-02	1.1E-02	1.7E-01	1.7E-01	1.0E-02	1.8E-02
	WT	EP001	EP253	EP332	EP336	EP340	EP344	EP348	EP352
CD8 ⁺ T Cells	9.9E+00	6.8E-02	1.6E-01	5.6E-01	1.2E-01	6.5E-01	8.0E-01	6.2E-01	3.8E-01
NK Cells	1.3E+00	1.0E-02	4.5E-02	8.6E-02	1.2E-02	9.2E-02	2.9E-01	1.3E-01	7.1E-02
T Regulatory Cells	3.8E-03	1.3E-02	1.8E-06	7.0E-02	1.1E-02	1.7E-01	1.7E-01	1.0E-02	1.8E-02
	WT	EP001	EP258	EP330	EP334	EP338	EP342	EP346	EP350
CD8 ⁺ T Cells	7.5E-01	3.1E-01	8.8E-02	1.6E+00	3.4E+00	9.1E-01	2.9E+00	3.2E-01	3.9E-01
NK Cells	3.2E-01	1.0E-02	7.6E-02	2.9E-01	ND	8.7E-02	1.2E+01	3.2E-02	7.6E-02
T Regulatory Cells	4.5E-05	1.4E-02	<1E-4	9.1E-01	6.6E-02	1.2E-01	3.0E-01	5.8E-03	4.0E-02
	WT	EP001	EP260	EP329	EP333	EP337	EP341	EP345	EP349
CD8 ⁺ T Cells	7.5E-01	3.1E-01	1.9E-02	9.6E-02	7.7E+00	6.6E-01	3.4E-01	1.6E+00	9.7E-02
NK Cells	3.2E-01	1.0E-02	2.7E-03	4.8E-03	7.5E-01	1.5E-02	1.7E-02	3.6E-01	1.1E-02
T Regulatory Cells	4.5E-05	1.4E-02	<1E-4	2.0E-02	3.4E-01	3.2E-02	4.5E-02	1.2E-01	ND

EXAMPLE 16

P-STAT5 ACTIVATION OF MURINE CELLS BY ENGINEERED IL2R α /IL2R β CLONES

5 Murine splenocytes were plated at 250,000 cells/well in a 96-well plate in 75 μ L of media. Cells were rested 1 hr at 37°C. Cells were stimulated with human IL2 WT and engineered His-Flag tagged IL2 at 4X concentration in 25 μ L for 20 min at 37°C. Stimulated mouse splenocytes were immediately fixed, permeabilized, stained

for cell lineage markers (CD3, CD56, CD4, CD8, FOXP3) and p-STAT5 and visualized on the Attune flow cytometer. CD8⁺ T cells were defined as CD3⁺CD56⁻CD4⁺CD8⁺. The % of cells that were p-STAT5⁺ was determined and graphed versus each IL2 titration (Figs. 31A-31D). A summary of the EC50 values of P-STAT5 activation in each cell type is shown in Fig. 34.

Isolated NK cells or mouse T regulatory cells were plated at 20,000 cells/well in a 96-well plate in 75 μ L of media. Cells were rested 1 hr at 37°C. Cells were stimulated with human IL2 WT and engineered His-Flag tagged IL2 at 4X concentration in 25 μ L for 20 min at 37°C. Stimulated mouse NK cells or mouse T regulatory cells were immediately fixed, permeabilized, stained for P-STAT5 and visualized on the Attune flow cytometer. The % of cells that were p-STAT5⁺ was determined and graphed versus each IL2 titration (Figs. 32A-32D, 33A-33D).

A summary of the EC50 values of P-STAT5 activation in each cell type is shown in Fig. 34.

15

EXAMPLE 17

DESIGN OF IL2R β AGONIST FC-FUSION PROTEINS

To generate bivalent IL2R β agonist Fc-fusion protein, the protein sequences encoding engineered IL2 polypeptides of EP003 (SEQ ID NO: 2), EP007 (SEQ ID NO: 4), EP002 (SEQ ID NO: 6), EP004 (SEQ ID NO: 09), EP001 (SEQ ID NO: 11), EP006 (SEQ ID NO: 16), EP009 (SEQ ID NO: 18), and EP005 (SEQ ID NO: 19) were fused to the N-terminal site of the constant frame sequence of human IgG1 isoform to produce engineered agonist-Fc fusion proteins (SEQ ID NOs: 44, 46, 48, 51, 53, 58, and 61). L234A, L235A and P329G mutations in the human IgG1 were introduced to eliminate complement binding and Fc- γ dependent antibody-dependent cell-mediated cytotoxicity (ADCC) effects (Lo et al., JBC 2017) (Fig. 35A).

To generate monovalent IL2R β agonist Fc-fusion protein, the protein sequences encoding engineered IL2 polypeptides of EP003 (SEQ ID NO: 2), EP007 (SEQ ID NO: 4), EP002 (SEQ ID NO: 6), EP004 (SEQ ID NO: 09), EP001 (SEQ ID NO: 11), EP006 (SEQ ID NO: 16), EP009 (SEQ ID NO: 18), and EP005 (SEQ ID NO:

19) were fused to the N-terminal site of the constant frame sequences of respective human IgG1 and IgG4 isoforms, to produce engineered agonist-Fc fusion proteins (SEQ ID NOs: 44, 46, 48, 51, 53, 58, and 61). The knob mutations of S354C, T366W and K409A were introduced to the constructs. The hole mutations of Y349C, T366S, L368A, F405K, Y407V were introduced to CH2 and CH3 fragments of IgG1 and IgG4, respectively. The L234A, L235A and P329G mutations in the human IgG1 were introduced to eliminate complement binding and Fc- γ dependent antibody-dependent cell-mediated cytotoxicity (ADCC) effects (Lo et al., JBC 2017) (Figs. 35B & 35C). The DNA encoding the entire Fc fusion agonist protein was then synthesized with codon optimized for mammalian cell expression, and subcloned to pCDNA3.4 (Invitrogen).

EXAMPLE 18

PRODUCTION OF IL2R β AGONIST FC FUSION PROTEINS

For bivalent IL2-Fc fusion protein production, the agonist was expressed transiently in ExpiHEK293-F cells in free style system (Invitrogen) according to standard protocol. The cells were grown in above conditions for seven days before harvesting. The supernatant was collected by centrifugation and filtered through a 0.2 μ m PES membrane. The Fc fusion agonist first was purified by MabSelect PrismA protein A resin (GE Health). The protein was eluted with 100mM Gly pH2.5 + 150mM NaCl and quickly neutralized with 20mM citrate pH 5.0 + 300mM NaCl. The agonist protein was then concentrated to 1 mL and further purified by a Superdex 200 Increase 10/300 GL column. The monomeric peak fractions were pooled and concentrated. The final purified protein has endotoxin of lower than 10EU/mg and kept in 20mM citrate pH 5.0 + 300mM NaCl. The purified IL2 - Fc fusion agonists were run on an SDS gel (4-12% Bis-Tris Bolt gel, with MES running buffer), comparing samples of each treated under reducing versus non-reducing conditions (Fig. 36A).

For monovalent IL2-Fc fusion protein production, the “knob” and “hole” constructs in respective IgG1 and IgG4 backbone format were transfected to ExpiHEK293-F cells with the ratio of 1:1. The cells were grown in above conditions for

five days before harvesting. The supernatant was collected by centrifugation and filtered through a 0.2 μ m PES membrane. The Fc fusion agonist first was purified by MabSelect Prisma protein A resin (GE Health). The protein was eluted with 100mM Gly pH2.5 + 150mM NaCl and quickly neutralized with 20mM citrate pH 5.0 +
5 300mM NaCl. The agonist protein was then concentrated to 1 mL and further purified by a Superdex 200 Increase 10/300 GL column. The monomeric peak fractions were pooled and concentrated. The final purified protein has endotoxin of lower than 10EU/mg and kept in 20mM citrate pH 5.0 + 300mM NaCl. The purified monovalent IL2 - Fc fusion agonists were run on an SDS gel (4-12% Bis-Tris Bolt gel, with MES
10 running buffer), comparing samples of each treated under reducing versus non-reducing conditions (Fig. 36B).

EXAMPLE 19

ELISA BINDING ANALYSIS OF IL2R β AGONIST FC-FUSION PROTEINS

For bivalent Fc-fusion proteins, human IL2R α , and human IL2R β were
15 each immobilized in a 384 well plate at final concentration of 2 μ g/mL in 1x PBS in total volume of 25 μ L per well. The plate was incubated overnight at 4°C followed by blocking with 80 μ L of superblock per well for 1 hour. The purified engineered IL2 mutant Fc fusion protein at 100 nM was 3-fold serial diluted 12 times. Each dilution was added to IL2R α and IL2R β wells in parallel. The engineered IL2 mutant binding
20 was detected by adding 50 μ L of anti-human Fc HRP diluted at 1:5000 in 1x PBST. In between each step, the plate was washed 3 times with 1x PBST in a plate washer. The plate was then developed with 25 μ L of TMB substrate for 5 mins and stopped by adding 25 μ L of 2N sulfuric acid. The plate was read at OD450 nm Biotek plate reader and the EC50 was analyzed with Prism 8.1 software. Absorbance versus IL-2
25 concentration is graphed for human IL2R α and IL2R β (Figs. 37A-37G). A summary of the EC50 values of ELISA binding is shown (Table 17).

Table 17. Summary of receptor binding analysis of bivalent IL2R β Fc fusion proteins

Clones	IL2 α	IL2 β	Relative activity	
	EC50	EC50	IL2R α	IL2R β
	(nM)	(nM)	(EC50: fold)	(EC50: fold)
EP085	5.0E-02	3.0E02*	1	1
EP079	6.4E-01	4.1E-01	-12.7	727
EP083	4.6E-02	2.8E-01	1.09	1079
EP082	2.8E-02	2.5E-01	1.78	1189
EP078	4.1E-02	2.1E+00	1.24	142
EP084	4.1E-02	2.6E+00	1.23	117
EP081	8.7E-02	2.0E-01	-1.73	1528
EP080	5.6E-02	2.3E-01	-1.17	1278

- For monovalent Fc-fusion proteins, recombinant His-tagged human IL2R α and IL2R β were added in 25 μ L of 1X PBS to wells of 384-well plate and incubated overnight at 4 °C to coat the plates. Plates were washed three times with 0.05% Tween20/1X PBS. Plates were blocked with 100 μ L of SuperBlock for 1 hr at RT and then washed 3 times with 0.05% Tween20/1X PBS. IL2 mutants were diluted in 0.05% Tween 20/1X PBS from 1000 nM to 0 nM and added to plates for 2 hrs at room temperature. Plates were then washed 6 times with 0.05% Tween20/1X PBS.
- Anti-HisTag-HRP was diluted 1:5000 in 0.05% Tween20/1X PBS and added to plates for 1 hr at RT. Plates were then washed 6 times with 0.05% Tween20/1X PBS, and TMB was added to develop blue color. Reactions were stopped with 2N hydrogen sulfide and light absorbance at 450 nm was read on a BioTek plate reader. Absorbance versus IL2 concentration is graphed for human IL2R α and IL2R β (Figs. 38A-38B). A summary of the EC50 values of ELISA binding is shown (Table 18).

Table 18. Summary of receptor binding analysis of monovalent IL2R β Fc fusion proteins

	EC50 (nM)	
	hIL2R α	hIL2R β
WT-Fc, Monovalent (EP290/EP280)	1.9E-02	9.4E+00
EP001, Monovalent (EP297/EP280)	2.7E+00	3.8E+00
EP003, Monovalent (EP291/EP280)	3.6E-01	6.0E-01

EXAMPLE 20

BINDING KINETICS OF MONOVALENT IL2R β FC FUSION PROTEINS

Binding kinetics of monovalent IL2R β Fc fusion proteins have been analyzed by SPR technology with Biacore T200. Briefly, anti-hFc antibody was

5 immobilized on flow cell 1 and 2. For each cycle, 1 μ g/mL of IL2 Fc fusion protein was captured for 60 seconds at flow rate of 10 μ L/min on flow cell 2 in 1XHBSP buffer on anti-hFc immobilized chip. 100 nM IL2R α -HIS tagged or IL2R β -HIS tagged was 2-fold serial diluted and injected onto both reference flow cell 1 and IL2 Fc fusion protein were captured at flow cell 2 for 150 seconds at flow rate of 30 μ L/min. 300 seconds

10 wash was applied after the last injection. The assay was set up with 8 serial diluted concentration points in 96 well format. The kinetics data was analyzed with Biacore T200 evaluation software 3.0. The specific binding response unit was derived from subtraction of binding to reference flow cell 1 from target flow cell 2 (Figs. 39A-39D).

EXAMPLE 21

15 P-STAT5 ACTIVATION OF HUMAN PBMCs BY IL2R β AGONIST FC-FUSION PROTEINS

Human PBMCs were isolated from peripheral blood and plated at 250,000 cells/well in a 96-well plate in 75 μ L of media. Cells were rested 1 hr at 37°C. Cells were stimulated with human IL2 WT and IL2R β agonist Fc-fusion proteins at 4X concentration in 25 μ L for 20 min at 37°C. Stimulated PBMCs were immediately fixed,

20 permeabilized, stained for cell lineage markers (CD3, CD56, CD4, CD8, FOXP3) and p-STAT5 and visualized on the Attune flow cytometer. CD8⁺ T cells were defined as CD3⁺CD56⁻CD4⁻CD8⁺. NK cells were defined as CD3⁻CD56⁺. T regulatory cells were defined as CD3⁺CD56⁻CD4⁺CD8⁻FOXP3⁺. The % of cells that were p-STAT5⁺ was determined and graphed versus each IL2 titration (Figs. 40A-40C for bivalent

25 fusion proteins and Figs. 41A-41C for bivalent fusion proteins; see Table 19 for a summary).

Table 19. Summary of P-STAT5 activation of human PBMCs by IL2R β agonist Fc-fusion proteins

	EC50 (nM)		
	CD8+ T Cells	NK Cells	T Regulatory Cells
WT-Fc, Bivalent (EP085)	1.4E+01	7.7E-02	2.8E-04
EP001-Fc, Bivalent (EP079)	1.1E-01	1.5E-02	2.7E-02
EP003-Fc, Bivalent (EP082)	3.4E-01	2.9E-02	1.9E-03
EP004-Fc, Bivalent (EP078)	8.4E-02	8.5E-03	5.9E-04
WT-Fc, Monovalent (EP290/EP280)	>5.0+01	>5.0+01	1.3E-02
EP001, Monovalent (EP297/EP280)	7.4E-01	1.6E-01	5.7E-02
EP003, Monovalent (EP291/EP280)	4.1E-01	9.4E-02	1.1E-02

EXAMPLE 22

IL2R β AGONIST MURINE IN VIVO PHARMACOKINETICS ANALYSIS

- 5 C57BL/6 mice were injected either i.v. or i.p. with 10 ug of IL2-WT, EP001, or EP003 in 200 uL of saline. Blood was collected at 0 min, 10 min, 30 min, 1 hr, 2 hrs, 4 hrs, 8 hrs, 16 hrs, 24 hrs and 48 hrs, and immediately centrifuged to separate out plasma. To determine plasma concentrations of IL2-WT and EP001, plasma was serially diluted and analyzed per instructions using the DuoSet IL2 ELISA kit (R&D
- 10 Systems). IL2-WT, EP001, and EP001 concentrations were determined by comparing absorbance values from plasma to spiked controls made in equally diluted untreated C57BL/6 mouse plasma. IL2 concentration is plotted versus time on a logarithmic scale (Figs. 42A-42B; Table 20).

Table 20.

	Dosing (i.v.)				Dosing (i.p.)		
	WT IL2	EP001	EP003		WT IL2	EP001	EP003
AUC (ng.h/mL)	81.9	266.71	170.37	AUC (ng.h/mL)	195.59	445.38	101.3
Clearance (mL/min/kg)	113.1	34.72	54.35	Cmax (ng/mL)	122.7	335.66	85.13
Volume of Distribution (L/kg)	10.85	3.16	5.25	Tmax (h)	2	1	1
T1/2 (h)	1.11	1.05	1.12	T1/2 (h)	0.47	0.56	0.61

EXAMPLE 23

IL2R β AGONIST MURINE IN VIVO TUMOR CELL INFILTRATION

Seven (7)-week old, female C57BL/6 mice were injected with 100,000 MC38 cells in 50% matrigel subcutaneously on their back flank. Tumors were

5 measured with calipers. Upon reaching an average volume of 100 mm³, mice were treated with 32 ug of WT IL2, EP001, EP003, or EP004 BID for 5 days. On day 6, mice were sacrificed and the tumor infiltrating immune cells were analyzed by flow cytometry. Tumor sections used for flow cytometry were weighed to obtain normalized cell counts. CD4⁺ T cells were defined as CD45⁺CD3⁺CD49b⁻CD4⁺CD8⁻. CD8⁺ T

10 cells were defined as CD45⁺CD3⁺CD49b⁻CD4⁻CD8⁺. NK cells were defined as CD45⁺CD3⁻CD49b⁺. T regulatory cells NK cells were defined as CD45⁺CD3⁺CD49b⁻CD4⁺CD8⁻FOXP3⁺. Naïve T cells were defined as CD44^{lo}CD62L^{hi}. Effector T cells were defined as CD44^{hi}CD62L^{lo} and central memory T cells were defined as CD44^{hi}CD62L^{hi}. The normalized counts of tumor infiltrating

15 immune cells (Figs. 43A-43D), the effector cell to regulatory cell ratios (Figs. 44A & 44B) and the T cell subtype (Figs. 45A-45C) are graphed versus IL2 clone treatment group.

CLAIMS

1. An engineered interleukin-2 (IL2) polypeptide comprising an engineered IL2 receptor β (IL2R β) binding region 2 motif comprising:
X₁-X₂-X₃-D-X₄-X₅-X₆-N-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃ (SEQ ID NO: 1),
wherein X₁, X₃, X₆, X₈, X₁₂, and X₁₃ each comprise any residue,
wherein X₂, X₄, and X₁₀ are uncharged residues,
wherein X₅, X₇, X₉, and X₁₁ each comprise uncharged, nonpolar residues, and
wherein the engineered IL2 polypeptide binds to IL2R β at a K_D at least 10-fold greater than a wild-type IL2.
2. The engineered IL2 polypeptide of claim 1, wherein X₁ is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue.
3. The engineered IL2 polypeptide of claim 1 or 2, wherein X₁ is selected from C, T, G, W, I, S, E, and K.
4. The engineered IL2 polypeptide of any one of claims 1-3, wherein X₁ is selected from G, K, E, C, and T.
5. The engineered IL2 polypeptide of any one of claims 1-4, wherein X₂ is an uncharged polar residue or an uncharged nonpolar residue.
6. The engineered IL2 polypeptide of any one of claims 1-5, wherein X₂ is selected from Y, P, V, W, L, A, and G.
7. The engineered IL2 polypeptide of any one of claims 1-6, wherein X₂ is selected from V, P, W, and A.
8. The engineered IL2 polypeptide of any one of claims 1-7, wherein X₃ is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue.

9. The engineered IL2 polypeptide of any one of claims 1-8, wherein X₃ is selected from S, T, Q, G, M, E, R, and K.
10. The engineered IL2 polypeptide of any one of claims 1-9, wherein X₃ is selected from T, G, S, R, and E.
11. The engineered IL2 polypeptide of any one of claims 1-10, wherein X₄ is not L.
12. The engineered IL2 polypeptide of any one of claims 1-11, wherein X₄ is an uncharged nonpolar residue or an uncharged polar residue.
13. The engineered IL2 polypeptide of any one of claims 1-12, wherein X₄ is selected from A, V, S, and T.
14. The engineered IL2 polypeptide of any one of claims 1-13, wherein X₅ is selected from I, L, T, and V.
15. The engineered IL2 polypeptide of any one of claims 1-14, wherein X₅ is selected from I and V.
16. The engineered IL2 polypeptide of any one of claims 1-15, wherein X₆ is an uncharged polar residue, a basic residue, or an acidic residue.
17. The engineered IL2 polypeptide of any one of claims 1-16, wherein X₆ is selected from S, T, E, D, and R.
18. The engineered IL2 polypeptide of any one of claims 1-17, wherein X₆ is selected from S, D, E, and T.
19. The engineered IL2 polypeptide of any one of claims 1-18, wherein X₇ is selected from I, A, M, and V.
20. The engineered IL2 polypeptide of any one of claims 1-19, wherein X₇ is selected from I, A, and M.

21. The engineered IL2 polypeptide of any one of claims 1-20, wherein X₈ is an uncharged polar residue, an uncharged nonpolar residue, a basic residue, or an acidic residue.
22. The engineered IL2 polypeptide of any one of claims 1-21, wherein X₈ is selected from S, T, N, Q, I, G, E, K, and R.
23. The engineered IL2 polypeptide of any one of claims 1-22, wherein X₈ is selected from I, R, N, and T.
24. The engineered IL2 polypeptide of any one of claims 1-23, wherein X₉ is selected from V, L, and I.
25. The engineered IL2 polypeptide of any one of claims 1-24, wherein X₉ is V.
26. The engineered IL2 polypeptide of any one of claims 1-25, wherein X₁₀ is an uncharged polar residue or an uncharged nonpolar residue.
27. The engineered IL2 polypeptide of any one of claims 1-26, wherein X₁₀ is selected from N, T, I, and L.
28. The engineered IL2 polypeptide of any one of claims 1-27, wherein X₁₀ is selected from I and L.
29. The engineered IL2 polypeptide of any one of claims 1-28, wherein X₁₁ is selected from V, A, and I.
30. The engineered IL2 polypeptide of any one of claims 1-29, wherein X₁₂ is an uncharged polar residue, an uncharged nonpolar residue, or an acidic residue.
31. The engineered IL2 polypeptide of any one of claims 1-30, wherein X₁₂ is selected from Q, L, G, K, and R.

32. The engineered IL2 polypeptide of any one of claims 1-31, wherein X₁₂ is selected from R, G, Q, and K.

33. The engineered IL2 polypeptide of any one of claims 1-32, wherein X₁₃ is an uncharged nonpolar residue or a basic residue.

34. The engineered IL2 polypeptide of any one of claims 1-33, wherein X₁₃ is selected from A, D, and E.

35. The engineered IL2 polypeptide of any one of claims 1-33, wherein X₁₃ is selected from E and A.

36. The engineered IL2 polypeptide of claim 1, wherein the engineered IL2R β binding region 2 is selected from: GVTDSISNAIVLARE (SEQ ID NO: 2); KWGDAVSNAIVLAGE (SEQ ID NO: 3); KWGDAVSNAIVLAGA (SEQ ID NO: 4); TLMDTTDNIGVLVRE (SEQ ID NO: 5); EPSDVISNINVLVQE (SEQ ID NO: 6); SPQDSIENISVLVRE (SEQ ID NO: 7); WASDSIENITLLIQE (SEQ ID NO: 8); CPTDTIENITVLIQE (SEQ ID NO: 9); RYKDSLENMQIIQE (SEQ ID NO: 10); TARDAVDNMRVIIQE (SEQ ID NO: 11); TPRDVVENMNVLVLE (SEQ ID NO: 12); TPSDVIENMEVLILD (SEQ ID NO: 13); TPSDAIENINVLIRE (SEQ ID NO: 14); TPSDVIENITVLVQE (SEQ ID NO: 15); GVGDTIDNINVLVKE (SEQ ID NO: 16); IGRDSIDNIKVIVQE (SEQ ID NO: 17); WATDTIRNVEVLVQE (SEQ ID NO: 18); TAEDVVTNITVLVQE (SEQ ID NO: 19); TAEDVISNIRVNVQE (SEQ ID NO: 20); and TPSDVIDNVSITVQE (SEQ ID NO: 21); TARDAISNIRVIVQE (SEQ ID NO: 210); RARDAIDNIRVIVQE (SEQ ID NO: 211); TPRDAIDNINVIIQE (SEQ ID NO: 212); TPRDAIDNIRVIVQE (SEQ ID NO: 213); TPRDAIDNIRVIILE (SEQ ID NO: 214); TARDAISNINVIIQE (SEQ ID NO: 215); and TARDAIDNINVIVQE (SEQ ID NO: 216); and TARDAIDNIRVIVLE (SEQ ID NO: 217).

37. The engineered IL2 polypeptide of claim 1, wherein the engineered IL2R β binding region 2 is selected from: TPRDAIDNIRVIVQE (SEQ ID NO: 213); TPRDAIDNIRVIILE (SEQ ID NO: 214); TARDAISNINVIIQE (SEQ ID NO: 215); and TARDAIDNINVIVQE (SEQ ID NO: 216).

38. The engineered IL2 polypeptide of claim 1, wherein the engineered IL2R β binding region 2 is selected from: GVTDSISNAIVLARE (SEQ ID NO: 2); KWGDAVSNAIVLAGA (SEQ ID NO: 4); EPSDVISNINVLVQE (SEQ ID NO: 6); CPTDTIENITVLIQE (SEQ ID NO: 9); TARDAVDNMRVIIQE (SEQ ID NO: 11); GVGDTIDNINVLVKE (SEQ ID NO: 16); TAEDVVTNITVLVQE (SEQ ID NO: 19).

39. The engineered IL2 polypeptide of claim 1, wherein the engineered IL2R β binding region 2 is selected from: GVTDSISNAIVLARE (SEQ ID NO: 2); CPTDTIENITVLIQE (SEQ ID NO: 9); and TARDAVDNMRVIIQE (SEQ ID NO: 11).

40. An engineered IL2 polypeptide comprising a substitution to at least one residue selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94.

41. The engineered IL2 polypeptide of claim 40, wherein the at least one residue is L85.

42. The engineered IL2 polypeptide of claim 40, comprising substitutions to at least two residues selected from: R81, P82, R83, L85, I86, S87, I89, N90, I92, V93, and L94.

43. The engineered IL2 polypeptide of claim 42, comprising substitutions to R81 and L85.

44. The engineered IL2 polypeptide of claim 43, further comprising a substitution to S87, N90, and L94.

45. The engineered IL2 polypeptide of claim 43, further comprising a substitution to S87, N90, and V93.

46. The engineered IL2 polypeptide of claim 43, further comprising a substitution to P82, and V93.

47. The engineered IL2 polypeptide of claim 46, further comprising a substitution to N90.

48. The engineered IL2 polypeptide of claim 42, wherein the at least two residues are selected from R81, R83, L85, I92, and L94.

49. The engineered IL2 polypeptide of claim 40, comprising substitutions to at least three residues selected from R81, R83, L85, I92, and L94.

50. The engineered IL2 polypeptide of claim 40, comprising substitutions to R81, R83, L85, I92, and L94.

51. The engineered IL2 polypeptide of claim 40, wherein:

- (a) the R81 substitution is selected from R81G, R81K, R81E, R81C, and R81T;
- (b) the R83 substitution is selected from R83T, R83G, R83S, and R83E;
- (c) the L85 substitution is selected from L85S, L85A, L85V, and L85T;
- (d) the I92 substitution is I92L; and
- (e) the L94 substitution is selected from L94R, L94G, L94Q, and L94K.

52. The engineered IL2 polypeptide of any one of claims 1-51, wherein the engineered IL2 polypeptide has an increase in affinity for IL2R β as compared to the wild-type IL2.

53. The engineered IL2 polypeptide of claim 52, wherein the engineered IL2 polypeptide has at least a 10-fold increase in affinity for IL2R β as compared to the wild-type IL2.

54. The engineered IL2 polypeptide of any one of claims 1-53, wherein the engineered IL2 polypeptide has a decrease in affinity for IL2R α as compared to wild-type IL2.

55. The engineered IL2 polypeptide of any one of claims 1-54, wherein the engineered IL2 polypeptide has a similar affinity for IL2R α as compared to wild-type IL2.

56. An engineered interleukin-2 (IL2) polypeptide comprising an engineered IL2 receptor α (IL2R α) binding region 1 comprising a substitution selected from: a substitution at position K35, a substitution at R38, a substitution at F42, a substitution at Y45, or any combination thereof, wherein the engineered IL2 polypeptide binds to IL2R α with at least 2-fold reduced binding kinetics as compared to wild-type IL2.

57. The engineered IL2 polypeptide of claim 56, comprising a substitution at position K35.

58. The engineered IL2 polypeptide of claim 57, wherein the substitution at position K35 comprises a non-basic residue.

59. The engineered IL2 polypeptide of claim 57, wherein the substitution at position K35 comprises an uncharged residue or an acidic residue.

60. The engineered IL2 polypeptide of claim 57, wherein the substitution at position K35 is selected from: K35G, K35L, K35S, K35V, K35D, K35E, and K35C.

61. The engineered IL2 polypeptide of any of claims 56-60, comprising a substitution at position R38.

62. The engineered IL2 polypeptide of claim 61, wherein the substitution at position R38 comprises a non-basic charged residue.

63. The engineered IL2 polypeptide of claim 61, wherein the substitution at position R38 comprises a uncharged residue or an acidic residue.

64. The engineered IL2 polypeptide of claim 61, wherein the substitution at position R38 is selected from: R38V, R38D, R38E, R38S, R38I, R38A, R38Y, R38G, R38C, or R38N.

65. The engineered IL2 polypeptide of any of claims 56-64, comprising a substitution at position F42.

66. The engineered IL2 polypeptide of claim 65, wherein the substitution at position F42 comprises an uncharged residue.

67. The engineered IL2 polypeptide of claim 65, wherein the substitution at position F42 comprises a positively charged residue.

68. The engineered IL2 polypeptide of claim 65, wherein the substitution at position F42 is selected from: F42A, F42R, F42G, F42I, F42L, F42P and F42H.

69. The engineered IL2 polypeptide of any of claims 56-68, comprising a substitution at position Y45.

70. The engineered IL2 polypeptide of claim 69, wherein the substitution at position Y45 comprises an uncharged residue.

71. The engineered IL2 polypeptide of claim 69, wherein the substitution at position Y45 comprises an uncharged polar residue or an uncharged non-polar residue.

72. The engineered IL2 polypeptide of claim 69, wherein the substitution at position Y45 is Y45S, Y45P, Y45A, Y45V, Y45C, Y45T, and Y45F.

73. The engineered IL2 polypeptide of any of claims 56-72, comprising a substitution at position K35 and a substitution at position R38.

74. The engineered IL2 polypeptide of claim 73, comprising a K35G substitution and R38E substitution.

75. The engineered IL2 polypeptide of any of claims 56-74, comprising a substitution at position K35 and a substitution at position F42.

76. The engineered IL2 polypeptide of claim 75, comprising a K35S substitution and an F42G substitution.

77. The engineered IL2 polypeptide of any of claims 56-76, comprising a substitution at position K35, a substitution at position R38, and a substitution at position F42.

78. The engineered IL2 polypeptide of any of claims 77, comprising a K35L substitution, an R38D substitution, and an F42R substitution.

79. The engineered IL2 polypeptide of any of claims 56-78, comprising a substitution at position R38 and a substitution at position Y45S.

80. The engineered IL2 polypeptide of any of claims 79, comprising an R38D substitution and an Y45S substitution.

81. The engineered IL2 polypeptide of any of claims 79, comprising an R38V substitution and an Y45S substitution.

82. The engineered IL2 polypeptide of any one of claims 56-81, comprising a substitution at at least one of positions K35, R38, F42, and Y45, wherein:

i) the substitution at position K35 is selected from: K35G, K35L, K35S, K35V, K35D, K35E, and K35C;

ii) the substitution at position R38 is selected from: R38V, R38D, R38E, R38S, R38I, R38A, R38Y, R38G, R38C, or R38N;

iii) the substitution at position F42 is selected from: F42A, F42R, F42G, F42I, F42L, F42P and F42H; and

iv) the substitution at position Y45 is Y45S, Y45P, Y45A, Y45V, Y45C, Y45T, and Y45F.

83. The engineered IL2 polypeptide of claim 82, wherein the substitution is at at least 2, at least 3, or all 4 of positions K35, R38, F42, and Y45.

84. The engineered IL2 polypeptide of any of claims 56-83, wherein the engineered IL2 polypeptide binds to IL2R α with at least 10-fold reduced binding kinetics as compared to wild-type IL2.

85. The engineered IL2 polypeptide of any of claims 56-84, wherein the engineered IL2R α binding region 1 is selected from: PVLTRMLTIKFY (SEQ ID NO: 183); PKLTRMLTLKFP (SEQ ID NO:184); PDLTSMLAFKFY (SEQ ID NO:185); PGLTEMLTFKFY (SEQ ID NO:186); PSLTRMLTGKFY (SEQ ID NO:187); PELTIMLTPKFY (SEQ ID NO:188); PCLTAMLTLKFA (SEQ ID NO:189); PCLTAMLTLKFA (SEQ ID NO:190); PKLTRMLTHKFV (SEQ ID NO:191); PCLTDMLTFKFY (SEQ ID NO:192); PLLTDMLTRKFY (SEQ ID NO:193); PLLTDMLTFKFY (SEQ ID NO:194); PKLTDMLTFKFS (SEQ ID NO:195); PKLTYMLTRKFY (SEQ ID NO:196); PKLTRMLTFKFC (SEQ ID NO:197); PKLTSMLTFKFS (SEQ ID NO:198); PKLTSMLTFKFS (SEQ ID NO:199); PKLTYMLTFKFS (SEQ ID NO:200); PKLTYMLTFKFS (SEQ ID NO:201); PKLTGMLTFKFS (SEQ ID NO:202); PKLTVMLTFKFT (SEQ ID NO:203); PKLTVMLTFKFS (SEQ ID NO:204); PKLTVMLTFKFP (SEQ ID NO:205); PKLTVMLTFKFF (SEQ ID NO:206); PKLTCMLTFKFA (SEQ ID NO:207); PKLTNMLTFKFA (SEQ ID NO:208); and PKLTNMLTFKFS (SEQ ID NO:209).

86. An engineered IL2 polypeptide comprising the engineered IL2 receptor β (IL2R β) binding region 2 of any of claims 1-55 and the engineered IL2 receptor α (IL2R α) binding region 1 of any of claims 56-85.

87. The engineered IL2 polypeptide of claim 86, wherein the engineered IL2R α binding region 1 is selected from: PVLTRMLTIKFY (SEQ ID NO: 183); PKLTRMLTLKFP (SEQ ID NO:184); PDLTSMLAFKFY (SEQ ID NO:185); PGLTEMLTFKFY (SEQ ID NO:186); PSLTRMLTGKFY (SEQ ID NO:187); PELTIMLTPKFY (SEQ ID NO:188); PCLTAMLTLKFA (SEQ ID NO:189); PCLTAMLTLKFA (SEQ ID NO:190); PKLTRMLTHKFV (SEQ ID NO:191); PCLTDMLTFKFY (SEQ ID NO:192); PLLTDMLTRKFY (SEQ ID NO:193); PLLTDMLTFKFY (SEQ ID NO:194); PKLTDMLTFKFS (SEQ ID NO:195); PKLTYMLTRKFY (SEQ ID NO:196); PKLTRMLTFKFC (SEQ ID NO:197);

PKLTSMLTFKFS (SEQ ID NO:198); PKLTSMLTFKFS (SEQ ID NO:199);
 PKLTYMLTFKFS (SEQ ID NO:200); PKLTYMLTFKFS (SEQ ID NO:201);
 PKLTGMLTFKFS (SEQ ID NO:202); PKLTVMLTFKFT (SEQ ID NO:203);
 PKLTVMLTFKFS (SEQ ID NO:204); PKLTVMLTFKFP (SEQ ID NO:205);
 PKLTVMLTFKFF (SEQ ID NO:206); PKLTCMLTFKFA (SEQ ID NO:207);
 PKLTNMLTFKFA (SEQ ID NO:208); and PKLTNMLTFKFS (SEQ ID NO:209); and
 wherein the engineered IL2R β binding region 2 is selected from:

GVTDSISNAIVLARE (SEQ ID NO: 2); KWGDAVSNARVLAGE (SEQ ID NO: 3);
 KWGDAVSNARVLAGA (SEQ ID NO: 4); TLMDTTDNIGVLVRE (SEQ ID NO: 5);
 EPSDVISNINVLVQE (SEQ ID NO: 6); SPQDSIENISVLVRE (SEQ ID NO: 7);
 WASDSIENITLLIQE (SEQ ID NO: 8); CPTDTIENITVLIQE (SEQ ID NO: 9);
 RYKDSLENMQIIQE (SEQ ID NO: 10); TARDAVDNMRVIIQE (SEQ ID NO: 11);
 TPRDVVENMNVLVLE (SEQ ID NO: 12); TPSDVIENTMEVLILD (SEQ ID NO: 13);
 TPSDAIENINVLIRE (SEQ ID NO: 14); TPSDVIENTITVLVQE (SEQ ID NO: 15);
 GVGDTIDNINVLVKE (SEQ ID NO: 16); IGRDSIDNIKVIVQE (SEQ ID NO: 17);
 WATDTIRNVEVLVQE (SEQ ID NO: 18); TAEDVVTNITVLVQE (SEQ ID NO: 19);
 TAEDVISNIRVNVQE (SEQ ID NO: 20); and TPSDVIDNVSITVQE (SEQ ID NO:
 21); TARDAISNIRVIVQE (SEQ ID NO: 210); RARDAIDNIRVIVQE (SEQ ID NO:
 211); TPRDAIDNINVIIQE (SEQ ID NO: 212); TPRDAIDNIRVIVQE (SEQ ID NO:
 213); TPRDAIDNIRVIILE (SEQ ID NO: 214); TARDAISNINVIIQE (SEQ ID NO:
 215); and TARDAIDNINVIVQE (SEQ ID NO: 216); and TARDAIDNIRVIVLE (SEQ
 ID NO: 217).

88. A fusion polypeptide comprising an engineered IL2 polypeptide of any one of claims 1-87 fused to a half-life extending molecule.

89. The fusion polypeptide of claim 88, wherein the half-life extending molecule comprises a half-life extending polypeptide.

90. The fusion polypeptide of claim 88, wherein the half-life extending polypeptide comprises an Fc domain, human serum albumin (HSA), an HSA binding molecule, or transferrin.

91. The fusion polypeptide of claim 88, wherein the half-life extending polypeptide comprises an Fc domain.

92. The fusion polypeptide of claim 88, wherein the half-life extending molecule comprises poly-ethylene glycol (PEG) or polypropylene glycol (PPG).

93. A fusion polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises an engineered IL2 polypeptide of any one of claims 1-87.

94. The fusion polypeptide of claim 93, wherein the second polypeptide comprises an antigen binding moiety.

95. The fusion polypeptide of claim 94, wherein the antigen binding moiety comprises an immunoglobulin.

96. The fusion polypeptide of claim 95, wherein the antigen binding moiety comprises a Fab molecule, an scFv, a bi-specific T-cell engager, a diabody, a single domain antibody, or a nanobody.

97. The fusion polypeptide of claim 93, wherein the second polypeptide comprises a cytokine.

98. The fusion polypeptide of claim 97, wherein the second polypeptide comprises interleukin 2, interleukin-15, interleukin-7, interleukin-10, or C-C motif chemokine ligand 19 (CCL19).

99. The fusion polypeptide of claim 93, wherein the second polypeptide comprises a second engineered IL2 polypeptide of any one of claims 1-87.

100. An isolated polynucleotide encoding at least one polypeptide of any one of claims 1-99.

101. An expression vector comprising the polynucleotide of claim 100.

102. A modified cell comprising the isolated polynucleotide of claim 100 or the expression vector of claim 101.

103. The modified cell of claim 102 further comprising an engineered T cell receptor or chimeric antigen receptor.

104. A pharmaceutical composition comprising the engineered IL2 polypeptide of any of claims 1-87, or the fusion polypeptide of any one of claims 88-99 and a pharmaceutically acceptable carrier.

105. An engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use in a method of modulating an immune response in a subject in need thereof.

106. The method of claim 105, wherein the modulating the immune response comprises at least one of: enhancing effector T cell activity, enhancing NK cell activity, and suppressing regulatory T cell activity.

107. An engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use in a method of treating a disease in a subject in need thereof.

108. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 107, wherein the disease comprises cancer or immunosuppression.

109. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 108, wherein the cancer comprises breast cancer, pancreatic cancer, lung cancer, glioblastoma, renal cell carcinoma, or melanoma.

110. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim

104 for use according to any of claims 107-109, wherein the subject is treated with an additional therapeutic agent.

111. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 110, wherein the additional therapeutic agent comprises an antigen binding moiety.

112. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 111, wherein the antigen binding moiety comprises a single domain antibody, a Fab molecule, an scFv, a diabody, a nanobody, a bi-specific T cell engager, or an immunoglobulin.

113. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 111 or 112, wherein the antigen binding moiety is directed to a tumor antigen.

114. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 110, wherein the additional therapeutic agent comprises an immune cell expressing a chimeric antigen receptor, an immune cell expressing an engineered T cell receptor, or a tumor infiltrating lymphocyte.

115. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 114, wherein the immune cell comprises a polynucleotide encoding the engineered IL2 polypeptide of any one of claims 1-87 or the fusion polypeptide of any one of claims 88-99.

116. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim

104 for use according to claim 110, wherein the additional therapeutic agent comprises an immune checkpoint inhibitor.

117. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 116, wherein the checkpoint inhibitor comprising a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a TIM3 inhibitor, a LAG3 inhibitor, a B7-H2 inhibitor or a B7-H3 inhibitor.

118. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 110, wherein the additional therapeutic agent comprises an oncolytic virus.

119. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 110, wherein the additional therapeutic agent comprises a tumor microenvironment (TME) inhibitor.

120. The engineered IL2 polypeptide of any one of claims 1-87, fusion polypeptide of any one of claims 88-99, or pharmaceutical composition of claim 104 for use according to claim 110, wherein the additional therapeutic agent comprises a cancer vaccine.

APTSSTKKTQLOLEHL LLDLOMILNGINNYKNPKLTRMLTEKFYMPKKA TELKHLQCLEF
ELKPLEEVNL AQSKNEHLRPRDLISNINVI VLELKGSETTFMCEYADETATIVEFLNRWI
TECQSIISTLT (SEQ ID NO: 22)

FIG. 1A

1/67




FIG. 1B



IL2R α binding loops (KD~ 10 nM)

IL2R β binding loops (KD>100 nM)

IL2R γ binding loops




FIG. 1C




FIG. 2A




FIG. 2B

Table 3. Mutagenic site sequence alignment of identified IL2Ra-reduced clones

Clone Name	34	35	36	37	38	39	40	41	42	43	44	45	SEQ ID NO:
WT IL2	P	K	L	T	R	M	L	T	F	K	F	Y	182
EP100	P	V	L	T	R	M	L	T	I	K	F	Y	183
EP101	P	K	L	T	R	M	L	T	L	K	F	P	184
EP102	P	D	L	T	S	M	L	A	F	K	F	Y	185
EP103	P	G	L	T	E	M	L	T	F	K	F	Y	186
EP104	P	S	L	T	R	M	L	T	G	K	F	Y	187
EP105	P	E	L	T	I	M	L	T	P	K	F	Y	188
EP106	P	C	L	T	A	M	L	T	L	K	F	A	189
EP107	P	C	L	T	A	M	L	T	L	K	F	A	190
EP108	P	K	L	T	R	M	L	T	H	K	F	V	191
EP109	P	C	L	T	D	M	L	T	F	K	F	Y	192
EP110	P	L	L	T	D	M	L	T	R	K	F	Y	193
EP111	P	L	L	T	D	M	L	T	F	K	F	Y	194
EP112	P	K	L	T	D	M	L	T	F	K	F	S	195
EP113	P	K	L	T	Y	M	L	T	R	K	F	Y	196
EP114	P	K	L	T	R	M	L	T	F	K	F	C	197
EP115	P	K	L	T	S	M	L	T	F	K	F	S	198
EP116	P	K	L	T	S	M	L	T	F	K	F	S	199
EP117	P	K	L	T	Y	M	L	T	F	K	F	S	200
EP118	P	K	L	T	Y	M	L	T	F	K	F	S	201
EP119	P	K	L	T	G	M	L	T	F	K	F	S	202
EP120	P	K	L	T	V	M	L	T	F	K	F	T	203
EP121	P	K	L	T	V	M	L	T	F	K	F	S	204
EP122	P	K	L	T	V	M	L	T	F	K	F	P	205
EP123	P	K	L	T	V	M	L	T	F	K	F	F	206
EP124	P	K	L	T	C	M	L	T	F	K	F	A	207
EP125	P	K	L	T	N	M	L	T	F	K	F	A	208
EP126	P	K	L	T	N	M	L	T	F	K	F	S	209

FIG. 3




FIG. 4

Mutagenic Libraries:




FIG. 5

**IL2 Mutant Library 2 Expression and Binding
Bacterial Supernatant Screening**




FIG. 6

9/67

Mutagenic site sequence alignment of identified IL2Rβ agonist clones																					SEQ ID NO:
Clone Name	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95						
WT IL2	R	P	R	D	L	I	S	N	I	N	V	I	V	L	E						68
EP003	G	V	T	D	S	I	S	N	A	I	V	L	A	R	E						2
EP008	K	W	G	D	A	V	S	N	A	R	V	L	A	G	E						3
EP007	K	W	G	D	A	V	S	N	A	R	V	L	A	G	A						4
EP020	T	L	M	D	T	T	D	N	I	G	V	L	V	R	E						5
EP002	E	P	S	D	V	I	S	N	I	N	V	L	V	Q	E						6
EP018	S	P	Q	D	S	I	E	N	I	S	V	L	V	R	E						7
EP011	W	A	S	D	S	I	E	N	I	T	L	L	I	Q	E						8
EP004	C	P	T	D	T	I	E	N	I	T	V	L	I	Q	E						9
EP016	R	Y	K	D	S	L	E	N	M	Q	I	I	I	Q	E						10
EP001*	T	A	R	D	A	V	D	N	M	R	V	I	I	Q	E						11
EP001*	T	A	R	D	A	V	D	N	M	R	V	I	I	Q	E						11
EP001*	T	A	R	D	A	V	D	N	M	R	V	I	I	Q	E						11
EP017	T	P	R	D	V	V	E	N	M	N	V	L	V	L	E						12
EP012*	T	P	S	D	V	I	E	N	M	E	V	L	I	L	D						13
EP012*	T	P	S	D	V	I	E	N	M	E	V	L	I	L	D						13
EP013	T	P	S	D	A	I	E	N	I	N	V	L	I	R	E						14
EP015	T	P	S	D	V	I	E	N	I	T	V	L	V	Q	E						15
EP006	G	V	G	D	T	I	D	N	I	N	V	L	V	K	E						16
EP019	I	G	R	D	S	I	D	N	I	K	V	I	V	Q	E						17
EP009	W	A	T	D	T	I	R	N	V	E	V	L	V	Q	E						18
EP005	T	A	E	D	V	V	T	N	I	T	V	L	V	Q	E						19
EP010	T	A	E	D	V	I	S	N	I	R	V	N	V	Q	E						20
EP014	T	P	S	D	V	I	D	N	V	S	I	T	V	Q	E						21

*Indicates sequences that were discovered more than once during the screening

FIG. 7

10/67





FIG. 8



WT IL-2 Binding to IL-2R α

ka (1/Ms)	kd (1/s)	KD (M)
1.811E+7	0.1438	7.938E-9

WT IL-2 Binding to IL-2R β

ka (1/Ms)	kd (1/s)	KD (M)
5.826E+4	0.2530	4.343E-6

FIG. 9A

FIG. 9B





FIG. 10A

FIG. 10B

EP005



13/67

FIG.10D

EP004




FIG. 10C




FIG. 10F




FIG. 10H




FIG. 10E




















FIG. 10G












FIG. 14A




FIG. 14C

FIG. 14B




FIG. 14E




FIG. 14F




FIG. 14H




FIG. 14I




FIG. 15B

FIG. 15A

EP001




FIG. 16B

EP253




FIG. 16D

WT IL2




FIG. 16A

EP250




FIG. 16C




FIG. 16F




FIG. 16H




FIG. 16E




FIG. 16G

25/67




FIG. 17




FIG. 18B




FIG. 18D




FIG. 18A




FIG. 18C




FIG. 18F




FIG. 18H




FIG. 18E






FIG. 18G



29/67




FIG. 19F




FIG. 19H




FIG. 19E




FIG. 19G





FIG. 20D




FIG. 20F




FIG. 20E








FIG. 20G






FIG. 21F




FIG. 21E




FIG. 21G




FIG. 22A




FIG. 22B




FIG. 23B




FIG. 23A




FIG. 23D




FIG. 23C






FIG. 23E






FIG. 25A

FIG. 25B




FIG. 25C

FIG. 25D




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 26D




FIG. 27A




FIG. 27C




FIG. 27B




FIG. 27D




FIG. 28A




FIG. 28B




FIG. 28C




FIG. 28D




FIG. 29A




FIG. 29B




FIG. 29C




FIG. 29D




FIG. 30A




FIG. 30C




FIG. 30B




FIG. 30D




FIG. 31B




FIG. 31D




FIG. 31A




FIG. 31C




FIG. 32B




FIG. 32D




FIG. 32A




FIG. 32C




FIG. 33B




FIG. 33D




FIG. 33A




FIG. 33C

49/67

		EC50 (nM)											
	mIL2	WT	EP001	EP252	EP331	EP335	EP339	EP343	EP347	EP351			
CD8+ T Cells	4.9E+00	4.6E+01	2.5E+00	9.2E+00	3.8E+01	3.8E+01	2.6E+01	2.5E+01	-	-			
NK Cells	1.2E+00	ND	1.7E+00	5.7E+01	8.4E+00	1.0E+01	7.0E+00	3.7E+00	5.6E+00	4.8E+00			
T Regulatory Cells	<1E-4	<1E-4	3.6E-02	<1E-4	4.1E-02	5.5E-01	5.4E+00	3.2E+00	<1E-4	1.3E-01			
	mIL2	WT	EP001	EP253	EP332	EP336	EP340	EP344	EP348	EP352			
CD8+ T Cells	4.9E+00	4.6E+01	2.5E+00	1.8E+01	2.7E+01	1.0E+01	3.1E+01	4.0E+01	-	-			
NK Cells	1.2E+00	ND	1.7E+00	4.4E+00	1.1E+01	2.1E+00	9.7E+00	1.0E+01	1.9E+01	5.4E+00			
T Regulatory Cells	<1E-4	<1E-4	3.6E-02	<1E-4	3.7E-02	1.4E-01	6.7E+00	6.4E-01	<1E-4	8.5E-02			
	mIL2	WT	EP001	EP258	EP330	EP334	EP338	EP342	EP346	EP350			
CD8+ T Cells	4.9E+00	4.6E+01	2.5E+00	3.4E+00	3.6E+00	5.2E+00	5.8E+00	6.3E+00	-	-			
NK Cells	1.2E+00	ND	1.7E+00	6.4E+00	1.1E+00	1.1E+00	1.4E+00	1.7E+00	3.3E+00	1.5E+00			
T Regulatory Cells	<1E-4	<1E-4	3.6E-02	<1E-4	5.1E-04	7.4E-02	1.3E+00	1.5E-01	<1E-4	2.7E-03			
	mIL2	WT	EP001	EP260	EP329	EP333	EP337	EP341	EP345	EP349			
CD8+ T Cells	4.9E+00	4.6E+01	2.5E+00	3.8E+00	3.9E+00	3.4E+01	4.2E-01	7.0E+00	-	-			
NK Cells	1.2E+00	ND	1.7E+00	9.8E-01	9.3E-01	1.5E+01	4.2E-01	1.1E+00	9.0E+00	3.6E+00			
T Regulatory Cells	<1E-4	<1E-4	3.6E-02	<1E-4	5.1E-03	4.4E-01	1.8E+00	1.6E-01	3.8E-02	3.0E-02			

FIG. 34




FIG. 35A

FIG. 35B

FIG. 35C




FIG. 36B











FIG. 36A








FIG. 38A

FIG. 38B




FIG. 39B




FIG. 39D




FIG. 39A




FIG. 39C




FIG. 40A




FIG. 40B




FIG. 40C




FIG. 41A




FIG. 41B




FIG. 41C

62/67




FIG. 42B




FIG. 42A




FIG. 43B




FIG. 43A




FIG. 43D




FIG. 43C




FIG. 44B




FIG. 44A




FIG. 45B




FIG. 45A




FIG. 45C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2020/046244

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-39(completely); 52-55, 86-120(partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2020/046244

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K14/52 A61K38/19 A61K38/20 C07K7/08 C07K14/55
C07K14/715 C12N15/62

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE UniProt [Online] 7 January 2015 (2015-01-07), Comor L.: "RecName: Full=Interleukin-2 {ECO:0000256 ARBA:ARBA00019453, ECO:0000256 RuleBase:RU363134}; Short=IL-2 {ECO:0000256 RuleBase:RU363134}; Flags: Fragment;", XP055741779, retrieved from EBI accession no. UNIPROT:A0A097KUR9 Database accession no. A0A097KUR9 sequence ----- -/--	1-4,8,9, 11-13, 19-23, 27,29, 33-35, 100

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 October 2020

Date of mailing of the international search report

21/12/2020

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Kools, Patrick

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2020/046244

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARON M. LEVIN ET AL: "Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'", NATURE, vol. 484, no. 7395, 25 March 2012 (2012-03-25), pages 529-533, XP055214333, ISSN: 0028-0836, DOI: 10.1038/nature10975 Whole document, especially figure 1 -----	1-39, 52-55, 86-120
A	WO 2008/003473 A2 (MERCK PATENT GMBH [DE]; GILLIES STEPHEN D [US]) 10 January 2008 (2008-01-10) Whole document, especially the claims and 0059 -----	1-39, 52-55, 86-120
A	SUMAN MITRA ET AL: "Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps", IMMUNITY, vol. 42, no. 5, 1 May 2015 (2015-05-01), pages 826-838, XP055718772, AMSTERDAM, NL ISSN: 1074-7613, DOI: 10.1016/j.immuni.2015.04.018 the whole document -----	1-39, 52-55, 86-120

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2020/046244

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008003473 A2	10-01-2008	AU 2007271398 A1	10-01-2008
		CA 2656700 A1	10-01-2008
		EP 2038417 A2	25-03-2009
		IL 196282 A	30-05-2013
		JP 2009542592 A	03-12-2009
		JP 2013100297 A	23-05-2013
		US 2008025947 A1	31-01-2008
		US 2013017168 A1	17-01-2013
		WO 2008003473 A2	10-01-2008

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-39(completely); 52-55, 86-120(partially)

Interleukin-2 polypeptides comprising an IL2 receptor binding region 1 motif of 15 amino acids with many variations and 2 defined residues, wherein the polypeptide binds to IL2Rbeta at a KD at least 10-fold greater than a wild-type IL2.

Fusion proteins comprising said IL2 polypeptide and a half-life extending molecule. Fusion protein comprising as first and second polypeptide a IL2 variant as previously claimed. Isolated polynucleotides encoding said polypeptides. Expression vector comprising the polynucleotide. Modified cells comprising the polypeptide or the expression vector. Pharmaceutical composition comprising the IL2 variant. Medical use formulated claims for the IL2 polypeptide variant, fusion protein and pharmaceutical composition.

2. claims: 40-51(completely); 52-55, 86-120(partially)

IL2 polypeptides comprising a substitution to at least one residue selected from: R81, P82, R83, L85, 186, S87, 189, N90, 192, V93, and L94.

Fusion proteins comprising said IL2 polypeptide and a half-life extending molecule. Fusion protein comprising as first and second polypeptide a IL2 variant as previously claimed. Isolated polynucleotides encoding said polypeptides. Expression vector comprising the polynucleotide. Modified cells comprising the polypeptide or the expression vector. Pharmaceutical composition comprising the IL2 variant. Medical use formulated claims for the IL2 polypeptide variant, fusion protein and pharmaceutical composition.

3. claims: 56-85(completely); 86-120(partially)

An IL2 polypeptide comprising an engineered IL2 receptor alpha (IL2Ra) binding region 1 comprising a substitution selected from: a substitution at position K35, R38, F42, and Y45, or any combination thereof, wherein the IL2 polypeptide binds to IL2Ra with at least 2-fold reduced binding kinetics as compared to wild-type IL2.

Isolated polynucleotides encoding said polypeptides. Expression vector comprising the polynucleotide. Modified cells comprising the polypeptide or the expression vector. Pharmaceutical composition comprising the IL2 variant. Medical use formulated claims for the IL2 polypeptide variant, fusion protein and pharmaceutical composition.
